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ABSTRACT
The wide adoption of electronic health records (EHRs), the unprecedented abundance of ge-
nomic data, and the rapid advancements in computational methods have paved the way for next
generation clinical decision support (NGCDS) systems. NGCDS provides significant opportunities
for the prevention, early detection, and the personalized treatment of complex diseases. The inte-
gration of genomic and EHR data into the NGCDS workflow is faced with significant challenges
due to the high complexity and sheer magnitude of the associated data.
This dissertation performs an in depth investigation to address the computational and algorith-
mic challenges of integrating genomic and EHR data within the NGCDS workflow. In particular,
the dissertation (i) defines the major genomic challenges NGCDS faces and discusses possible res-
olution directions, (ii) proposes an accelerated method for processing raw genomic data, (iii) in-
troduces a data representation and compression method to store the processed genomic outcomes
in a database schema, and finally, (iv) investigates the feasibility of using EHR data to produce
accurate disease risk assessments. We hope that the proposed solutions will expedite the adoption
of NGCDS and help advance the state of healthcare.
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1. INTRODUCTION
Making good healthcare decisions is of paramount importance for improving the lives of indi-
viduals and the society at large. A growing body of evidence indicates that the integration of intel-
ligent clinical decision support (CDS) technologies into the clinical workflow can reduce medical
errors, improve patient safety, and enhance patient outcomes [1]. The wide adoption of EHRs, the
unprecedented abundance of genomic data, and the rapid advancements in computational methods
have paved the way for NGCDS.
EHR and genomic data provide significant opportunities for the prevention and early detection
of complex diseases, devising personalized treatment plans, and the delivery of precision medicine
[1, 2]. EHRs store various forms of data that capture the different aspects of clinical care includ-
ing diagnosis, medical procedures, prescribed medication, laboratory test results and radiological
imaging data. Furthermore, the significant reduction in sequencing cost presented strong moti-
vation for integrating genomic technologies into the clinical workflow. Consequently, genomic
information is likely to be routinely produced for most patients in the foreseeable future.
The integration and utilization of these two data sources presents arduous challenges due to
their high complexity and sheer magnitude. Therefore, the implementation of NGCDS requires
the development of innovative methods to meet its computational demands and harness its ability
to improve healthcare. This dissertation performs an in depth investigation to address the com-
putational and algorithmic challenges of integrating genomic and EHR data within the NGCDS
workflow. Since genomic data is a newer type of data, and since genomic data exceeds EHR data
in size and complexity, it faces a larger set of challenges than EHR data. Consequently, we ded-
icate Chapters 2, 3, and 4 to tackle important genomic NGCDS aspects. However, as Chapter 5
demonstrates, EHR integration also faces critical challenges as well. We dedicate Chapter 5 to
address one of the main challenges of EHR integration into NGCDS. An overview of the topics
discussed in each chapter of the dissertation is provided below.
In Chapter 2, we provide a detailed discussion for the genomic integration aspects based on
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an in-depth analysis of the extant literature. We divide genomic integration into a series of seven
intertwined integration aspects spanning the different stages of the NGCDS workflow. For each
of the integration aspects, we focus on the research directions outlined by the nation’s leading
consortia that aim to establish guidelines for genomic integration [3, 4, 5, 6]. We then describe the
current and future applications for genomic integration and summarize its prospects for improving
healthcare. Finally, we provide an overview of the current collaborations working towards this
integration.
The integration aspects we tackle are as follows:
 Which genetic variations and locations should be targeted by the genomic data generation
process?
 Which technology and platform should be used to generate the genomic data?
 How will the genomic data be processed?
 How should genomic data be represented, stored, and transmitted?
 Which genomic knowledge bases should be used to interpret genomic data?
 How to produce clinically relevant conclusions from genomic data?
 How should clinical genomic outcomes be presented?
We also discuss the main genomic NGCDS areas, which have recently witnessed an increased
adoption or exhibit substantial promise to be routinely carried out in the near future.
Finally, we provide an overview of three projects funded by the National Human Genome
Research Institute (NHGRI) that aim to achieve genomic integration within NGCDS. These con-
sortia are tackling the genomic integration problem from complementary angles, which we briefly
describe. The chapter concludes by specifying directions for future NGCDS innovation.
In Chapter 3, we introduce a parallel algorithm to perform Next Generation Sequencing (NGS)
read alignment. Read alignment is one of the first stages in the processing pipeline of NGS raw
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data. NGS platforms typically produce millions of read sequences. Each read needs to be aligned
against the reference genome in order to find its mapping location in the presence of genomic vari-
ations. NGS read alignment is one of the most time consuming stages in the genomic processing
pipeline. Our algorithm uses the hardware properties of the Central Processing Unit (CPU) and
Graphics Processing Unit (GPU) to resolve the main bottlenecks encountered in the read alignment
process. The proposed design exploits the GPU’s massive parallelism to hide memory access la-
tency by aligning hundreds of reads concurrently. The alignment process is applied to NGS reads
in batches. Multiprocessing is used to concurrently load, process, and save multiple read batches.
We perform a number of experiments to examine the performance of the proposed algorithm and
compare it to popular read alignment algorithms.
In Chapter 4 we propose a method for representing genetic variations (genotypes) in database-
driven applications. The wide adoption and utilization of genotype information in genomic studies
prompts the development of efficient data storage and access methods. Most current methods rely
heavily on text files to store, retrieve, and transport their data. Recently, there has been increasing
interest in adopting a database representation for genotype information. Adopting a database repre-
sentation is particularly important for developing genomic web applications and service-oriented
architecture (SOA) genomics frameworks [7] [8]. In our approach, we break up the patient’s
genome into continuous regions, each containing a fixed number of DNA nucleotides. These ge-
nomic regions are represented within a data structure called a 2D bitmap. The sparse nature of
genotype information enables our 2D bitmap representation to achieve a high level of compress-
ibility, which significantly reduces storage requirements. We discuss the implementation of our
bitmap representation in this chapter. We also conduct a series of three experiments to evaluate the
different aspects of the bitmap representation and to compare it to other database representations.
In Chapter 5, we investigate the feasibility of conducting disease risk assessment from in-
complete EHR records. The wide adoption of EHR systems makes them promising platforms for
NGCDS disease prediction and detection methods. Clinicians often utilize disease risk assessment
models to evaluate the patient’s current and future risk of contracting diseases such as cancer, dia-
3
betes, or heart failure[9]. However, these models could not be directly applied to EHR data. In the
past few years, there have been several attempts to implement EHR-based risk assessment models.
However, EHR records are often incomplete and typically include a large amount of missing data
[10, 11, 12]. This limits the applicability of EHR-based risk assessment models to the rare cases
where all the information required by the model is available.
In this chapter, we introduce a probabilistic strategy for performing EHR-based Coronary
Artery Disease (CAD) risk estimation. The proposed method combines probability distribution
analysis, mixed-effects linear modeling, and Bayesian updating to produce accurate CAD risk as-
sessments. This proposed method has three main characteristics: (i) dynamic: the model undergoes
updates as new data is made available, (ii) population specific: the model is driven by EHR data
and therefore it inherently accounts for the characteristics specific to the EHR patient population.
(iii) patient-level: the model produces CAD risk assessment score for each patient in the EHR
meeting the model’s basic requirements. Finally, we compare our method to competing methods
proposed in the literature.
We summarize the findings of this dissertation in the Conclusion section. We hope that the
work presented in this dissertation would help improve the state of healthcare through expediting
the implementation and adoption of NGCDS.
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2. UNDERSTANDING THE GENOMIC INTEGRATION CHALLENGES OF NEXT
GENERATION CLINICAL DECISION SUPPORT
2.1 Introduction and literature review
Genomic knowledge is advancing at a revolutionary pace, which is elevating interest in inte-
grating this knowledge with clinical applications to improve the quality of healthcare. Information
about the genetic profile of a patient can reveal valuable information about the genetic disease-
contributing factors and can eventually aid in the detection, diagnosis, and treatment of a wide
range of complex diseases [13].
However, this integration is riddled with many challenges spanning many aspects including
social, ethical, legal, educational, economic, and technical challenges. From an NGCDS point of
view, integrating genomic data into the clinical process includes an overwhelming number of chal-
lenges and implementation directions [3, 14, 15]. Addressing these challenges involves answering
fundamental questions about the purpose of the integration. The integration process also entails
answering questions related to how this data will be generated, analyzed, stored, and ultimately
used in conjunction with medical data.
Generating clinically relevant conclusions from genomic and clinical data presents a number of
problems of its own [14, 16, 17]. It entails gathering knowledge from dispersed sources, choosing
useful information, analyzing it against the patient’s genomic and clinical data, and drawing con-
clusions. This requires using a long list of connected genomics tools and applications, which could
differ widely depending upon the type of analysis to be run. Since the interpretation of genomic
information requires a specialized skill set that goes beyond most clinicians’ formal training, the
integration process should allow for input from several domain experts like genomics lab profes-
sionals, geneticists, and genetic counselors. Furthermore, the outcomes of this process should be
presented in a way that is easily understood by healthcare professionals [3, 18, 17, 19]. This re-
 c 2017 IEEE. Reprinted, with permission, from Al Kawam, Ahmad, Arun Sen, Aniruddha Datta, and Nancy
Dickey, "Understanding the Bioinformatics Challenges of Integrating Genomics into Healthcare.", IEEE Journal of
Biomedical and Health Informatics, 2017.
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quires carefully choosing the information to be presented, the format in which it is to be presented,
and the level of interaction that is required from the domain experts or clinicians.
Several papers in the literature have addressed clinical genomic integration [20, 21, 22, 23, 3].
However, these papers primarily focused on the social, ethical, legal, educational, and economic
challenges of this integration, or merely provided a higher level discussion of the bioinformatics
challenges of various integrations [24]. On the other hand, few papers have examined specific
technical aspects of this process. In Louie et al. [25] the authors addressed the data management
challenges inherent in integrating genomic data into clinical practice. The paper discussed the data
management solutions that could be used to store and access large-scale genomic data efficiently.
Kho et al [8] discussed the issue of integrating genomic data into EHRs. In particular, the au-
thor studied the practical challenges of storing unstructured genetic test results of large size and
complexity into a structured database. Genomic data has a unique set of characteristics that dif-
ferentiates it from other medical data and thus it requires special considerations for its integration
with EHR systems. In Masys et al [26], the authors specified a list of seven desiderata for integrat-
ing genomics into EHRs and then discussed the common practices in each category. In Kawamoto
et al [15] the authors defined an Information Technology (IT) scheme for integrating genomic data
with CDS systems. CDS is the process of transforming medical observations into actionable clin-
ical outcomes through a set of rules and guidelines. Welch et al, [27] defined seven desiderata for
integrating genomic data with CDS after providing an IT model for the CDS integration in [28].
In this chapter, we provide a detailed discussion for the genomic NGCDS integration aspects,
based on an in-depth analysis of the extant literature. Tackling the numerous genomic integration
challenges of NGCDS all at once could be overwhelming. Consequently, in this work, we divide
these challenges into a series of seven intertwined integration aspects spanning the different stages
of the NGCDS workflow, as visualized in Figure 2.1. For each of the integration aspects, we focus
on the research directions outlined by the nation’s leading consortia that aim to establish guidelines
for clinical genomics integration [3, 4, 5, 6]. We then describe the current and future applications
for clinical genomic integration and summarize the advantages of this integration for improving
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Figure 2.1: The clinical genomic integration workflow. Reprinted, with permission, from [29]. c
2017 IEEE.
healthcare. Finally, we provide an overview of the current collaborations working towards this
integration and discuss three case studies of existing clinical genomic systems.
2.2 Genomic integration challenges of NGCDS
As with many NGCDS research areas, clinical genomic integration lacks a defined general
structure. The healthcare institutions that have already deployed clinical genomic processes tai-
lored their implementations to suit their specific aims. Nonetheless, when we examined these
implementations and compared them with an exhaustive list of papers that address the technical
challenges of integration, a structured pattern emerged. Using a careful analysis of the literature,
we were able to define a series of 7 consequential and intertwined questions that are needed to be
addressed in order to enable clinical genomic integration. The direction taken at each inquiry will
have implications on the inquiries to follow. Therefore, making a decision at each of the following
questions has to follow an overall strategy. The NGCDS genomic integration aspects are presented
below.
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2.2.1 Which genetic variations and locations should be targeted by the genomic data gener-
ation process?
The term genomic data engulfs a diverse set of genomic data subtypes. Different genomic data
subtypes could unveil information about different kinds of genetic variations [13]. Therefore, and
in order to determine which genomic data subtype should be generated, a decision should be made
about which genetic variations to target.
Genomic data could portray information about several types of genetic variations. This in-
cludes small genetic variations such as Single Nucleotide Polymorphisms (SNPs), and Inser-
tions/deletions (Indels). SNPs are differences of one nucleotide base between the target and refer-
ence sequences. In some cases a single SNP can cause a genetic disorder. Studies have found that
the presence of several SNPs could lead to the development of complex diseases [30]. Indels, on
the other hand, occur when a small fragment of Deoxyribonucleic acid (DNA) is added or deleted
at a certain position in the patient’s genome. When present in protein coding regions, an indel
could have severe effects. When changes occur in these regions, the resulting protein might lose
its functionality, which might cause the development of disease or even death.
Genomic data could also be used to find larger genetic variations known as structural variations,
which include Inversions and Copy Number Variations (CNVs). Inversions occur when a long
stretch of DNA is present in the patient’s genome in its reverse complement form. Inversions have
been associated with a number of diseases such as Haemophilia A [31] and Hunter syndrome [32].
CNVs on the other hand occur when a long DNA fragment is repeated in the patient’s genome
several times more, or less, than normal. CNVs have been associated with a number of diseases
and disorders including cancer [33] and autism [33].
Genomic data could go beyond DNA sequence variations to cover information about the ex-
pression levels of different genes. This information could be used to determine which genes are
active and which ones are suppressed. Certain gene expression profiles have been found to have
strong connections to several diseases [34, 35].
In addition to the genetic variations that occur in the genomic sequence itself, it is worth men-
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tioning that there is an additional type of variation usually studied that occurs in the messenger
Ribonucleic Acid (mRNA) sequence transcribed from the gene sequence. The human genome con-
tains consecutive exon (coding) and intron (non-coding) regions. DNA is transcribed into mRNA
by removing the intron regions and joining neighboring exon regions. The process of joining con-
secutive exons is called splicing. Alternative Splicing (AS) occurs when the splicing mechanism
skips over an exon while it is joining consecutive exons, or when the splicing mechanisms joins
two exons that are not typically joined together. AS introduces more genetic diversity in living
organisms. However, some alternative splicing variants might cause the development of diseases
such as cancer [36]. In addition to AS, mRNA data could be used to determine the expression of
the genes they are associated with.
Deciding on which type of genetic variation to target depends on the clinical genomic appli-
cation to be implemented. For example, while screening for sickle-cell anemia, information about
the SNPs occurring in the beta-globin gene is required [37]. In other applications, gene expression
profiles have been used to detect biomarkers for diseases such as breast cancer [35]. There are
numerous databases [38, 39, 40] that store information that relates genetic diseases to genetic vari-
ants. For example, the Online Mendelian Inheritance in Man database (OMIM) currently stores
information about 3,319 genes that contribute to 4,898 single-gene disorders and traits. After de-
ciding on a genomic application, these databases should be studied to identify the relevant genetic
variations that need to be identified through genetic testing. Information about the relevant genetic
variants should be curated, including information about the genetic elements they interact with and
the genomic location at which they occur. When all the relevant genetic variants are identified,
DNA samples could be extracted from the patient, which then undergo a genomic data generation
process using a genomic data generating platform.
The National Institutes of Health reports that there are over 2000 genetic tests available to de-
tect rare and common medical conditions. However, these genetic tests are often underutilized due
to insufficient training or lack of communication within the clinical team. For example, in a recent
study [41], physicians agreed that genetic tests could improve diagnosis accuracy. However, many
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physicians reported that they were not aware of all the genetic tests that are available and in some
cases were not sure which genetic test should be ordered. To address these issues, several health-
care institutions have established training programs that aim to introduce the genetic services avail-
able and familiarize physicians with the processes for ordering them. Another approach to address
this problem is to provide access to genetic consultants in order to assist physicians in ordering
genetic tests and interpreting their results. However, in the future, a more efficient approach would
be provided by clinical genomic decision support systems, which would automatically recommend
genetic tests to the physician according to the patient’s clinical profile.
2.2.2 Which technology and platform should be used to generate the genomic data?
The genomics field currently offers two main types of high throughput technologies: Microar-
ray technologies, and NGS technologies, with the latter gaining significant popularity in the past
few years.
2.2.2.1 Next generation sequencing
NGS technologies are the successors of the Sanger sequencing technology used in sequenc-
ing the human genome. Sequencing utilizes chemical and engineering methods to determine the
nucleotide sequence of a DNA segment at a single base resolution. The fundamental change that
transformed sequencing technology was adopting a strategy that relies on the sequencing of short
reads in a massively parallel fashion instead of sequencing a few very long reads.
Once prohibitive, the costs of genetic sequencing have significantly decreased throughout the
past decade, which have contributed to NGS’s wide adoption. Two NGS applications, Whole
Genome Sequencing (WGS) and Targeted Sequencing (TS), have been at the center of most ge-
nomic clinical applications. As the name suggests, WGS determines the nucleotide sequence of
the patient’s entire genome which is then used to call out mutations that could be causing, or could
eventually lead to, the development of disease. TS, on the other hand, determines the nucleotide
sequence of specific locations in the genome. These two applications are increasingly used in
screening applications, such as determining if the patient is a carrier for sickle cell disease. These
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platforms also hold great promise for improving personalized treatment plans in the future.
In addition to clinical applications, there are two preclinical NGS applications that have gained
notable adoption, namely ribonucleic acid sequencing (RNA-Seq) and chromatin immunoprecipi-
tation sequencing (ChIP-Seq). RNA-Seq is used to determine the abundance of mRNA sequences
in the patient’s cells. This information is then used to determine the expression level of the patient’s
genes. ChIP-Seq on the other hand targets the binding sites of epigenetic factors, which control
numerous operations in the cell. These two preclinical applications enable clinical researchers to
further understand the developmental processes of diseases in order to devise better treatments and
interventions.
NGS technologies have been implemented in a variety of platforms, which differ in sequencing
cost, accuracy, and read length. Platforms that output shorter reads have higher throughputs and
lower sequencing cost. However, shorter reads usually present challenges in the downstream anal-
ysis. Therefore, a trade-off between cost, throughput, and analysis complexity should be reached
when deciding on a sequencing platform.
2.2.2.2 DNA microarrays
The DNA microarray, also known as a DNA-Chip, is a prefabricated plate, typically made of
glass. The chip includes short, synthetic, single-stranded DNA sequences, called probes, repre-
senting a fragmented genetic region. Probes are used to perform high-throughput screening for
genetic markers in an individual’s DNA.
Several DNAMicroarrays platforms have been widely used to detect different types of variants.
In clinical settings, the most widely used DNA Microarray technology are SNP-arrays, which are
used to determine the allelic values of targeted genes. Today, SNP-arrays are capable of detecting
more than one million different human SNPs with high accuracy and reproducibility. In addition to
SNP-arrays, comparative genomic hybridization arrays (aCGH) have been also used in clinical set-
tings to detect genomic deletions and duplications which are known to be associated with diseases.
aCGH is a powerful tool for detecting submicroscopic chromosomal abnormalities and has been
used to detect genetic birth abnormalities. In preclinical settings, gene-expression profiling assays
11
and chip-chip assays have been used to study gene expression and epigenetic factors, respectively.
DNA microarrays are an efficient method for screening a large number of genetic variations as
long as information about the variation such as its location and sequence is known. NGS technolo-
gies on the other hand can reveal the DNA sequence of genomic locations with little reliance on
prior information about the genetic variations in that region. However, Microarrays are generally
considered easier to use. The sample preparations required by Microarrays are generally less com-
plicated and less labor-intensive than NGS. Choosing a technology and platform for generating
genomic data comprises making a strategic decision, which takes into consideration constraints on
time, cost, and type of information to be procured.
2.2.3 How will the genomic data be processed?
The generated genomic raw data needs to go through several preprocessing and analysis steps
before it could be used in the clinical decision process. Genomic data preprocessing extracts or en-
hances meaningful data characteristics and prepares the dataset for further analysis [42]. Genomic
analysis, on the other hand, aims to infer genetic variations information from the preprocessed data
while minimizing detection errors. The genomic analysis workflows might differ depending on the
type of genomic data available and the technology that has been used to produce it.
2.2.3.1 Next generation sequencing workflow
NGS technologies typically produce millions of DNA sequences (reads) per run. However,
these reads often contain machine artifacts in the form of errors in the DNA sequence. Fortunately,
these platforms also provide a quality measure of the sequenced bases, which is used to filter out
the low quality parts of the read. After quality filtering, the next preprocessing step is finding
the locations where the reads align on the reference genome. Read alignment is one of the most
well studied problems and has been addressed by a variety of tools [43]. The raw read sequences
from the NGS machine are then analyzed through different workflows depending on the target
application.
NGS analysis studies the variations that occur in the DNA sequence such as SNPs, Indels, and
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structural variations. Variant identification algorithms are applied to locate genomic variations such
as SNPs, indels, inversions and CNVs. Rigorous statistical methods are applied to identify variants
with strong evidence for existence. These methods usually incorporate sequencing quality scores,
alignment quality scores, and comparing the variant with similar variant occurring in individuals of
a study cohort or population [44]. The statistically relevant variants identified are then assessed for
biological significance. For example, variants that could disrupt a biological process are identified.
An impact score for each variant could be calculated through tools such as Polyphen2 [45] and
SIFT [46].
In applications where RNA-Seq data is produced instead of DNA data, some modifications to
the preprocessing and analysis have to be made. Since an mRNA transcript is made up exclusively
of exons, the read aligner must be able to handle spliced alignment [47]. The analysis of RNA-
Sequencing data involves the detection of splice junction locations through the reconstruction of
mRNA transcripts [48]. RNA-Seq data could also be used in gene-expression profiling through
calculating the read count value for each transcript [49].
2.2.3.2 Microarray workflow
Instead of reads, Microarray platforms produce a continuous signal for each probe, called in-
tensity. The processing of this data usually involves two main steps: filtering and normalization
[42]. In filtering, erroneous probes are removed. These could include quality control probes,
probes discovered to hybridize to the incorrect strand, probes with annotation warning, and probes
with noisy signals. Furthermore, the probe intensities undergo data transformations and normaliza-
tion to account for systematic differences across datasets and enable correct comparison between
different probes. Normalization insures that differences stemming from technical artifacts are not
mistaken to be of biologically origin. After filtering and normalization, the processing workflows
of microarray data diverge depending on the genetic variation targeted. For example, in gene ex-
pression profiling, differential expression analysis is carried out to determine the genes having a
statistically significant change in expression level. In CNV detection for example, CNV detection
tools and algorithms [50] are used to detect differences in hybridization levels among consecutive
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probes. In SNP arrays, the normalization step is followed by SNP calling [51], which determines
which allele of each targeted SNP the patient has. The results of these workflows are then used in
down stream clinical genomic analysis to determine their link to disease.
Although the accuracy of genomic analysis workflows has significantly improved in the past
few years, they are still facing a major issue when it comes to the consistency of their results. This
challenge stems from the wide variety of tool options that could be used to perform each step of the
analysis. It has been reported that different combinations of tools often have discrepancies in their
results [52, 53]. In the absence of standardized analysis workflows, these variations impose chal-
lenges for the reproducibility of test results and could therefore diminish confidence in them. This
issue also highlights the importance of keeping track of the tools and databases that were used in
producing the results, which will be discussed in depth in the next subsection. Furthermore, NGS
analysis workflows tend to have very long run times, typically extending for days. This forms a
throughput bottleneck for wide-scale clinical implementations. Recently, parallel platforms such
as distributed systems and cloud computing have been utilized to accelerate computationally ex-
pensive steps in the analysis workflow [43]. However, these solutions are still in the experimental
phase and are yet to be used in clinical settings.
2.2.4 How should genomic data be represented, stored, and transmitted?
The technologies used to generate genomic data and their processing workflows are constantly
undergoing changes and updates. For example, the human reference genome has undergone at
least 18 updates in the last 16 years. Although the frequency of genome updates has decreased in
the past few years, a significant number of tools and genomic knowledge bases still rely on older
versions of the reference genome. Different reference genome versions usually include differences
in haplotype calls and considerable annotation variations. Consequently, using the wrong refer-
ence version could lead to errors in locating important genetic elements such as genes, SNPs, and
epigenetic motifs.
Versioning also plays an important role in the interpretation and knowledge generation phase
of the genomic integration process. After identification, genetic variants are examined for their
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medical relevance through comparing them against the accumulated knowledge in clinical genomic
databases. These databases undergo constant updates as new links between genetic elements and
biological processes are unveiled. Therefore, it is imperative that clinical genomic applications
keep track of the database version which was used to assess the relevance of the genetic variants.
As we will discuss later in the manuscript, negative results do not necessarily mean that the tested
variant has no biological significance. It could simply mean that biological value is yet to be
discovered for this variant. Therefore, keeping track of the versioning information is necessary for
maintaining the data and for triggering updating procedures and alerts.
Metadata management is the de facto method for keeping track of versioning information.
Metadata is defined as data that describes the data and is used for providing important versioning
information about the analysis process. This includes information about what platform was used to
generate the data, the softwares that were used during preprocessing, analysis, and interpretation.
In addition, metadata usually provides a biological context such as the age, gender, and disease
status of the individual whose genetic data is being analyzed. It could also contain information
about environmental exposures and medical conditions. It is worth mentioning that integration of
EHR information with genomic data would provide an extensive biological context for the analysis
and interpretation phases which could lead to more accurate results. Currently, most genomic
workflows rely on textual descriptions to communicate the metadata associated with a genomic
dataset. The conception of unified machine-readable metadata standards is currently considered to
be one of the most pressing challenges in clinical genomics.
Another challenge in devising a data storage strategy would be deciding on the stage in the
analysis process at which the genomic data should be stored. Several factors play a role in making
a decision on whether to store genomic data in its raw form, post-processing form, or in one of
the several intermediate forms. For example, the significant updates might sometimes requires the
preprocessing and analysis workflow to be rerun in order to produce more accurate results in the
downstream analysis. Consequently, having access to the raw genomic data is advantageous for
ensuring reproducibility [27]. However, storing raw genomic variants comes with several caveats.
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The most noticeable of these is that genomic data generation platforms typically produce gigabytes
of data for each patient. Therefore, in wide-scale clinical genomics implementations, storage of
raw data might present a considerable challenge. This is particularly the case for data produced
using NGS sequencing platforms where it is commonplace to see raw data files reaching up to
hundreds of gigabytes of data from whole-genome sequencing studies. As a consequence, data
warehousing methods have been used to address the storage requirements of raw genomic data
[54]. In addition to capacity, storing raw genomic data poses processing time challenges. The
processing workflow typically has long runtimes ranging from a few hours to a few days, which is
impractical for many time-critical clinical genomics applications.
To alleviate storage challenges, an intermediate or post-processing form of the data could be
stored. Size and processing time of genomic data decreases significantly at each subsequent pro-
cessing step. Table 1 shows an example of the genomic data file sizes and processing times at
each intermediary processing step in an NGS whole exome sequencing experiment. As can be
observed from the table, storing the data in a processed format can significantly reduce the storage
and processing requirements. A suitable data format for storage would be produced at a suffi-
ciently advanced step in the workflow such that, on the one hand, it has a reasonable size and does
not require long further processing times, and on the other hand, it is less prone to updates and
modifications to the processing methods used. For example, in the NGS whole genome/exome se-
quencing workflow researchers have found that the Variant Calling Format (VCF) is very suitable
for storage. [55]
Genomic data chosen for storage should be represented in a format that facilitates further anal-
ysis and integration with other types of clinical data. Currently most genomics applications rely on
formatted text files as a form of data representation. However, very recently, several approaches
have been proposed to integrate genomic data within the EHR system through a database repre-
sentation.
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Table 2.1: A comparison of file-type sizes and processing times for an NGS whole-exome sequenc-
ing experiment. Reprinted, with permission, from [29]. c 2017 IEEE.
Data Type Size Processing time Information
FASTQ 10 GB 23 Hrs. Raw Sequences
BAM 7 GB 15 Hrs. Mapped Sequences
Pre-analysis VCF 100 MB 5 Hrs. All called variants
Post-analysis Variants 3 MB – Potentially important
high-quality variants
The experiment was run on an Intel i7@2.3GHz workstation with 32GB of memory for a typical
human whole-exome dataset.
2.2.4.1 Text-based methods
Most current genomic analysis applications rely on text files as a form for their input/output
representation. To allow for communication between multiple tools, several text formats have been
developed. One of the basic and most common text format methods used by several genomics tools
is the tab-separated values (TSV) format, which utilizes tab-delimited columns to describe different
fields and rows to represent instances. TSV files are used to represent several types of genomic
data including raw microarray data, gene expression data, CNV data, and in some cases, SNP
data. TSV files are usually accompanied by metadata, which provides more information about
the type and purpose of each TSV field. Furthermore, other standards have been developed to
represent genomic data at specific stages in the genomic analysis workflow. For example, in NGS
applications, FASTQ is used to represent unaligned read data, SAM format is used to represent
aligned read data, and finally, VCF and MAF are used to represent SNP data.
Text-based data representation is convenient for typical genomic applications where data needs
to be loaded once prior to analysis and only needs to be written when the results are produced.
However clinical applications usually use a database representation to allow integration between
multiple applications under time-sensitive settings.
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2.2.4.2 Database methods
Representing genomic data using a database approach has been the target of several conceptual
modeling approaches, which used entity relationship models to represent the different relationships
within genomic data and between them and other data types. For example, the Ensemble Variant
Database (EVD) is one of the well-established database techniques to store NGS variant data.
EVD enables the efficient representation of massive amounts of variants and allows for fast access
to these variants through a specialized application programming interface (API).
In clinical settings, patient data is represented within electronic health records, which store in-
formation about the patient’s medical record, personal information, familial history of disease, and
other relevant information. To facilitate the integration between genomic data and other healthcare
data, several methods have been proposed. For example, [7] very recently tackled the issue of
integrating cancer genomic data into electronic health records. Several paradigms for integration
were discussed including i) implementing a custom interface between genomic data generation
sources and the EHR, ii) developing middleware to tie both genomic and healthcare infrastructure
together, and iii) implementing a standardized encoded representation of genomic data, queried
using standardized APIs. In [5] the authors describe the implementation of the Clinical Implemen-
tation of Personalized Medicine through Electronic Health Records and Genomics (CLIPMERGE)
Pharmacogenomics project, which integrates pharmacogenomics testing data with EHR data. In
this implementation, the genomic data is stored in a separate database, which communicates with
Mount Sinai’s EHR system to fulfill queries and send warnings and alerts to the physician. The
road towards integration between genomics data and EHR systems is riddled with complexities. In
[8] the authors studied the practical challenges of storing unstructured genetic test results of large
size and complexity into the EHR system. In [26], the authors specify a list of seven desiderata for
integrating genomics into EHRs. Establishing EHR integration is still an open research issue and
will most likely remain so in the foreseeable future.
Regardless of which storage and representation strategy is used, data security measures need
to be taken to ensure the protection of the patient’s medical and genomic information. The Health
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Insurance Portability and Accountability Act (HIPAA) specifies a list of 18 identifiers referred to
as protected health information (PHI). Under HIPAA, the storage, access, and transmission of PHI
data has to comply with a set of standards. For example, the system should implement access con-
trol and authentication procedures that restrict the disclosure of PHI data to authorized users. The
system should also implement procedures for obtaining necessary PHI during an emergency. Fur-
thermore, the system needs to implement procedures to record and examine activity in the stored
health records to protect against malicious or unauthorized access. Encryption and decryption
mechanisms are required during the storage and transmission of PHI data as an additional safe
guard for protecting the patient’s information.
The numerous regulations associated with PHI data pose a considerable inconvenience for
the analysis of health information. However, and in order to facilitate analysis, PHI data usually
undergoes a de-identification step in which any information that could link the health data to a
particular patient are removed. After analysis, the results are re-identified by authorized personnel
and stored in the HIPAA compliant system.
The integration of genomics data and health information has introduced new challenges for
protecting the privacy of patient information. For instance, HIPAA doesnt include DNA sequence
data as a regulated health identifier. The more recent Genetic Information Non-Discrimination Act
(GINA) has amended the HIPAA security rule to state that genetic information is considered health
information. However, the amendment did not clarify when genetic information becomes identi-
fiable. Current practices rely on expert opinion in determining whether a particular set of genetic
information should be protected or disclosed. Many researchers and healthcare professionals have
argued that re-identification could be possible from currently de-regulated genetic data [56]. As
a result, more concise regulations need to be introduced in the future to insure the protection of
patient information. The implications of such regulations on the informatics infrastructure are yet
to be known.
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2.2.5 Which genomic knowledge bases should be used to interpret genomic data?
The genomic data resulting from the processing workflow is used to reach clinically relevant
conclusions regarding the patient’s condition. However, this cannot be achieved without analyzing
the generated information in light of clinical genomic knowledge. In this paper we define clinical
genomic knowledge as the collective understanding of the genetic contributors to disease. Un-
derstanding the function of genes, their interaction among themselves, and their interaction with
other components in the cell enhances this knowledge. Unfortunately, these aspects are far from
being fully understood and thus genomic knowledge is limited. Nonetheless, the boundaries of
knowledge are expanding rapidly as new discoveries unfold.
Clinical genomic knowledge is dispersed across different databases. These knowledge databases
differ significantly in their scopes and kind of information they hold. From a clinical genomics per-
spective, we can classify knowledge bases into three categories:
2.2.5.1 Clinically-actionable knowledge bases
This type of genomic knowledge databases is the most useful for clinical genomic integration.
It encompasses two types of knowledge:
 Rules and guidelines for clinical action: In this category, clinical genomic knowledge exists
as a set of discrete rules that govern the relationship between genotype and phenotype. Un-
fortunately, most fields of clinical genomic research have not yet reached a level of maturity
to produce such rules. Nonetheless, one particular field, namely pharmacogenomics, has
proved that the formulation of genotype-phenotype rules could be achieved. An example of
these databases is pharmGKB [57], which curates drug dosage guidelines and recommenda-
tions produced, based on the genetic alleles present.
 Verified, reproducible, and high confidence genotype-phenotype mappings: This type of
knowledge bases includes reliable relations, which could be directly used to make clinically
relevant conclusions. Several knowledge bases of this category exist and are publically avail-
able such as ClinVar [40], OMIM [38], and The Single Nucleotide Polymorphism database
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(dbSNP) [39]. These databases usually provide information about the relationships between
genetic variations and the phenotype they affect, in addition to the evidence for this relation.
Variant-phenotype relations are usually sent to these knowledge bases where they undergo
an approval process by a panel of experts before being published. Domain experts and com-
putational programs can use this information to produce clinical action recommendations.
2.2.5.2 Genomic study catalogues
This type of databases stores data and results from studies that investigate genetic variation
expression in phenotypes. The primary goal of these databases is to provide the clinical genomic
research community with large-scales of data to infer new genotype-phenotype mappings. Hence,
the data in these catalogues cannot be directly used for producing clinical decisions. The results
of these experiments are usually anchored to the experimental settings under which they were con-
ducted. They also require further analysis and verification to establish confident mapping between
the genotypes they study and the phenotypes they report. Nonetheless, the information included in
these databases can provide further evidence about the function of a genetic element when com-
pared across multiple studies. An example of these databases is genome-wide association studies
(GWAS) catalogue [58], which stores the results of different GWAS studies, the dbGaP [59], which
stores the results and data of studies that investigate the relationships between genotypes and phe-
notypes, and the cancer genome atlas [60] which stores 2.5 petabytes of data describing tumor
tissue and matched normal tissues from more than 11,000 patients.
2.2.5.3 Genomic Enrichment Resources
The goal of these databases is to store information about genetic elements and their interac-
tions. This category includes databases that record information about genes, genomic variants,
gene networks, and molecular pathways. In clinical settings, this knowledge is used in furthering
the healthcare professional’s understanding about the patient’s condition to produce more accurate
conclusions. Examples of these databases include dbSNP, Gene Ontology (GO), and the Kyoto En-
cyclopedia of Genes and Genomes (KEGG). The dbSNP resource stores information about SNPs,
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such as their physical mapping, functional analysis, and their association to disease. GO on the
other hand, stores information about gene function and the relationships between different gene
functions. KEGG is a resource for understanding high-level functions and utilities of the biologi-
cal system. For instance, KEGG includes information about the interactions of a certain gene with
its relevant proteins and molecular pathways.
2.2.6 How to produce clinically relevant conclusions from genomic data?
Utilizing genomic knowledge to draw conclusions from large-scale genomic patient data is a
challenging research problem that has been gaining vast attention throughout the past decade. Nu-
merous approaches have been proposed to handle the knowledge-data integration issues throughout
the literature and in practice. These approaches vary widely in complexity and degree of human
involvement. We divide the knowledge-data integration into four approaches: two computationally
driven and two expert-driven approaches. By ’expert-driven’, we refer to approaches in which a
human expert ultimately makes the clinically relevant conclusions, although these conclusions are
often assisted by computational methods.
2.2.6.1 Annotation approach
Annotation refers to the process of using genomic knowledge stored in databases to annotate
the patient’s genomic data with information that could help predict its phenotypic consequences.
This approach is mainly used for DNA-Sequencing data, which is composed of the patient’s ge-
nomic variants. By accessing databases such as RefSeq [61], UCSC genes [62], Ensembl [63],
GENCODE [64], and several others, the variant’s locations are mapped to their corresponding
genes. Since genes are usually associated with phenotypes, therefore, knowing a variant’s genomic
location can help identify the phenotypes it is associated with. Furthermore, several tools such as
SIFT [46], Polyphen2 [45], and MutationTaster [65] could be used to calculate a severity score
for each variant. This score represents the variant’s ability to disrupt the function of downstream
products, such as mRNA molecules and proteins. Annotation also involves accessing genotype-
phenotype mapping databases such as OMIM, dbSNP and ClinVar . These databases store infor-
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mation about variations that have been associated with diseases. Although most of these tasks
could be done manually, several annotation tools have been developed to automate this process.
Examples of these tools are ANNOVAR [66], VEP [67], and SnpEff [68]. Although computational
methods are used in most steps of the annotation process, this approach relies on the expertise of a
domain expert, usually in genetics and pathology, to connect the pieces of information retrieved to
draw a conclusion.
2.2.6.2 Visualization approach
Visualization is typically used to display data as a part of reporting mechanisms for users. In
genomics research, it has taken an added responsibility to integrate genomic information with ge-
nomic knowledge. Flexible and interactive visualization tools enable healthcare professionals to
explore the genomic data without knowing what patterns to expect and without doing any statis-
tical and analytical work with the data. In the early days of genomic research, the visualization
tools were created mainly for displaying annotated sequence data [69]. Recent visualization ef-
forts, on the other hand, are more broadly focused. For example, Geneways [70] extracts abstracts
of articles pertinent to molecular biology, analyzes interactions between molecular substances and
visualizes the molecular networks; Genoviz [71] provides a mechanism for incorporating adaptive
and dynamic zooming to allow rapid navigation and exploration of genome-scale data sets covering
from chromosomes to genes to individual base pairs; Integrative Genomics Viewer [72] supports
intuitive real-time exploration of diverse, large-scale genomic data sets ranging from aligned se-
quence reads, mutations, copy number, RNA interference screens, gene expression, methylation
and genomic annotations. Similar to the annotation approach, visual information about the pa-
tient’s genetic variants are displayed to a domain expert who, based on collective analysis of the
data, produces clinically relevant conclusions about the patient’s case.
2.2.6.3 Analytics approach
Analysis approaches utilize statistical and algorithmic methods to draw conclusions from data.
In particular, these methods use established disease biomarkers to calculate a probability of pa-
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tient having a positive diagnosis at the time of testing or in the future. These biomarkers in-
clude the genomic variations discussed earlier in this section, such as SNPs, CNVs, and abnormal
gene-expression levels. Numerous statistical and algorithmic methods have been proposed in the
literature to address this issue. For instance, several methods have been created using Bayesian ap-
proaches and Markov modeling. Machine learning and data mining have also been used in disease
diagnosis and prediction [73, 74, 75].
Although the application of analytical methods is very promising, it still faces serious chal-
lenges in providing high confidence results. This is particularly the case for complex diseases such
as cancer, diabetes, and heart disease. Unlike Mendelian diseases, complex diseases cannot be
traced back to a single gene or mutation. They are usually the result of interactions between several
genetic, transcriptional, epigenetic, and environmental factors. Consequently, one-dimensional
genomic biomarker discovery methods result in low-confidence markers with limited utility. For
example, the GWAS analysis has been found to detect SNPs that explain only a tiny portion of
the total phenotypic variation. Furthermore, most of the detected SNPs lie within the non-coding
regions of the genome that are not associated with any genes, therefore not yielding a clear inter-
pretation for the disease. Gene expression biomarkers on the other hand have been found to yield
high false positive and false negative rates at the early developmental stage of the disease which
hinders their usefulness.
Accurate biomarker detection requires the development of sophisticated models that account
for these levels of interactions to overcome the limitations of current methods. Recent advances
in functional genomics have made promising advancements in biomarker discovery through in-
tegrating GWAS information with gene networks and biological pathways. Concurrently, other
researchers are combining genotyped SNPs with gene-expression information to verify the cur-
rently held assumption that the intronic SNPs detected by GWAS analysis play a role in regulating
the gene expression of nearby genes. Furthermore, there has been an increased interest in integrat-
ing SNP and gene expression information with epigenetic ChIP-Seq information which could aid
in identifying multilevel biomarkers. Finally, there have been recent attempts for using genomics
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data in conjunction with EHR data to improve diagnosis and produce disease risk predictions
[76, 77, 78]. Furthermore, national efforts have been launched in the past few years targeted at in-
troducing new analytics methods for using clinical and genomic data to improve healthcare quality
[5, 6]. With these advancements, analytical approaches show a great promise for reaching accurate
disease prediction and diagnosis in the near future.
2.2.6.4 Rule-engine approach
The most straightforward form of clinical genomic knowledge exists as a set of discrete rules
that govern the relationship between genotype and phenotype. Most fields of clinical genomic
research have not reached a level of maturity to produce such rules. Nonetheless, one particular
field, namely pharmacogenomics, has proved that the formulation of genotype-phenotype rules can
be achieved. These rules are utilized for delivering precision medicine and devising personalized
treatment plans. Pharmacogenomics research has shown that the response to certain medications
can be affected by the patient’s genetic profile. For example, cancer treatments vary in sensitiv-
ity depending on the mutations that exist in the cancerous somatic cells. Consequently, somatic
mutation testing is increasingly becoming a standard procedure in contemporary cancer therapies.
Another instance that utilizes rule-based approaches for the delivery of precision medicine is
the prescription of neurological medications such as Clomipramine and Carbamazepine. Recent
studies have shown that the metabolism of these drugs is highly affected by the patient’s genetic
profile. Due to the serious unfavorable interactions these medications might cause, strict guidelines
have been adopted in several countries, such as Canada and Austria, which require genetic testing
before these drugs could be prescribed. The goal of reaching accurate prescription guidelines and
dosages is an active research topic pursued by numerous research groups around the world, most
notabily,the Clinical Pharmacogenomics Implementation Consortium (CPIC) [79], Pharmacogene
Variation Consortium (PharmVar), the Royal Dutch Association for the Advancement of Pharmacy
(DPWG) [80], and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) [81].
The main database that stores precision medicine dosage guidelines is PharmGKB [57]. These
guidelines are utilized by a rule-engine, which is a piece of software that could apply a set of rules
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Table 2.2: Examples of pharmacogenomics rules for rule-based outcome assessment. Reprinted,
with permission, from [29]. c 2017 IEEE.
Substance Source Rule Recommendation
Allopurinol CPIC If patient is HLA-B*58:01-
positive
Significantly increased risk of allopurinol
scar. Allopurinol is contraindicated
ClomipramineDPWG If patient has one of
the CYP2C19 genotypes
(*2/*2,*2/*3,*3/*3)
Increased risk for reduced response to
clopidogrel. Consider alternative drug.
CarbamazepineCPNDS In patients who are positive
for HLA-B*15:02 or HLA-
A*31:01
Alternative medications should be used as
first-line therapy
on large-scale patient data. In this scenario, pharmacogenomics guidelines need to be expressed
in a format that could be parsed by the rule engine. An example of such rules is given in Table
2. The rule-engine approach has been recently used at both the Mount Sinai Hospital though
the CLIPMERGE Pharmacogenomics project and at the Vanderbilt University Medical Center
through the Predict project (Pulley et al, 2012) [82]. With the decrease of genetic testing costs
and the robustness of the rule-based approach, further clinical adoption of these methods should
be witnessed in the near future.
2.2.7 How should clinical genomic outcomes be presented?
The conclusions drawn from clinical genomic data need to be presented to the clinician in a
clear, concise, and timely manner. However, due to the complexity of genomic information and
lack of sufficient training, most clinicians find difficulty in using the results in the clinical process.
Consequently, creative, effective and informative data reporting techniques should be used to help
communicate the information to the physician. In healthcare there are two main computerized
forms of communication for outcome delivery:
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2.2.7.1 Informative Clinical Genomic Reports
This report details the clinical genomic implications associated with the patient’s data. This in-
cludes diagnosis suggestions, medical procedure recommendations, and drug response predictions.
Due to the complexity of genomic information, these reports should be enriched with educational
material and links to external resources to enhance the clinicians´ understanding of the patient’s
case. Clinical genomics reports could be manually written by one or more specialists and might
include separate sections to study the patient’s case from the perspective of different domain ex-
perts. The report could also be generated automatically using knowledge base rules and resources.
For example, at The New EXome Technology in Medicine (NEXT Medicine) project at the Uni-
versity of Washington and at the The NCGENES (North Carolina clinical Genomic Evaluation by
Next-generation Exome Sequencing) project at the University of North Carolina at Chapel Hill, the
clinical genomic integration process produces reports which provide links to supporting materials
to enhance the clinician’s understanding of the patients´ variants [4].
2.2.7.2 Notifications and alerts
Some healthcare applications, such as CDS systems use rules to produce notifications and
alerts to communicate case specific recommendations and warnings. This form of communication
is mainly used in pharmacogenomics applications where alerts are used to alert the clinician about
possibly dangerous gene-drug interactions when prescribing medication. In the CLIPMERGE
project for example, the pharmacogenomics clinical risk assessment engine is interfaced with
Mount Sinai’s EHR system, which includes an embedded CDS. Through this interface, the phar-
macogenomics engine could send messages to the CDS for issuing alerts to the clinician. Other
methods for notifying the clinician include rule-triggered popup alerts, email notifications, and
text message alerts. According to the literature [15] there is no clear study that favors one form of
delivery over another. Consequently, hospitals vary significantly in their outcome delivery mecha-
nisms. For example, The Baylor College of Medicine and the Brigham and Women’s Hospital use
emails stripped from protected information to notify clinicians of the genomic analysis findings.
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They provide verbal explanations for more complex cases. At Brigham and Womens Hospital,
the emails provide links to further information summarized into a patient genetic information ta-
ble, which is integrated into the EHR [4]. The effectiveness of these methods for communicating
results, however, is yet to be determined. Consequently, more studies into this area are needed
to determine which notification method can deliver adequate information while enabling a timely
response by the clinician.
Another possible application for notifications and alerts is to inform the clinician about changes
in the patient’s results. Due to the complexity of the analysis process, and the error proneness of
each step, a negative result does not necessarily mean a disease causing genetic variant does not
exist. An erroneous negative result could be caused by a variety of reasons such as missing one
or more relevant variants when ordering the genetic testing, encountering machine errors during
the profiling process, calling false negatives during the processing phase, or reaching a wrong
conclusion in the analysis phase. Therefore, the assessment of a patient’s health profile might
exhibit multiple changes after the initial assessment. This brings us back to the importance of
tracking metadata which records the versioning information of the tools and knowledge bases that
were used in the assessment process.
The patient’s assessment could also change in view of new clinical information coming to light.
This includes a new disease diagnosis, the prescription of a new drug, or any updates in the patient’s
personal information. CDS applications, such as disease risk assessment, frequently use clinical
information in conjunction with genomic information to produce their outcomes. Therefore, an
effective genomic clinical decision system should be able to keep track of any changes in the
patient’s clinical information in order to flag those patients who should undergo reassessment.
However, since genomic clinical decision support is a new area of research, the implementation of
these notification and alerts procedures is yet to be described.
2.3 Discussion
Genomic data could be applied to a wide range of clinical applications. In this section, we
discuss the main clinical genomic integration areas, which have recently witnessed an increased
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adoption or exhibit substantial promise to be routinely carried out in the near future.
 Diagnostic testing. It aims to determine the genetic cause of the patient’s disease. Up to
the date of this publication, the OMIM [38] repository reports 4898 disorders and traits that
are a consequence of genetic variation in a single gene. Using this information, diagnostic
genetic tests are regularly being developed to detect disorders. Recently, genetic diagnostic
tests have been made available for several genetic disorders including inherited retinal de-
generation, hearing loss, cardiomyopathies, mitochondrial disorders and cancer [83, 84, 85].
 Pre-symptomatic genetic tests. These tests are applied as precautionary measures for patients
to assess their risk of contracting disease or to determine their carrier status. This is partic-
ularly useful for individuals who might have a genetic predisposition due to their familial
history or ethnic background. For example, individuals might have a high risk of being a
carrier of autosomal recessive disorders such as sickle cell anemia, cystic fibrosis, Fragile X
Syndrome, and spinal muscular atrophy.
 Cancer somatic mutation tests. Somatic mutations occur in non-germ cells during the life-
time of the individual. These mutations are not inherited from the patient’s parents and are
not passed on to their offspring. The accumulation of these alterations might in some cases
lead to the development of cancer [86]. Consequently, profiling the patient’s somatic mu-
tations has become a widely adopted procedure in clinical settings [87, 88]. In addition to
cancer risk prediction and diagnosis, these tests can aid in creating personalized treatments
for cancer patients [89]. Cancer drugs are usually effective in targeting mutation-carrying
cells. However, the sensitivity of these drugs varies depending on the genetic makeup of the
individual tumors. Therefore, the profiling of the tumor DNA can enable the admission of a
more guided and effective anti-cancer therapy.
 Pre-implantation, pre-Natal and newborn screening. These genetic tests aim to detect harm-
ful genetic conditions that could result in genetic disorders in the child. Pre-implantation
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testing is used in assisted reproductive techniques such as in-vitro fertilization whereas pre-
natal screening is performed through either invasive or non-invasive methods during preg-
nancy. Newborn screening is performed right after birth and is required by-law in all US
states for some disorders. These methods are used to detect chromosomal and gene irregu-
larities to better inform the parents and physician of the possible disease risks and to prompt
early treatment in newborns.
 Pharmacogenetic testing. The patient’s genetic profile is used to find the most suitable drugs
for treatment, modify the drug dosage, and alert the clinician of dangerous drug-gene inter-
actions. Information about the patient’s genetic profile could enable the prescription of more
effective cancer drugs thus achieving better results and improving the patient’s experience.
Pharmacogenomics information has proven to be useful in the treatment and management of
heart disease, asthma, depression and many other common diseases [90].
NHGRI has funded three main national consortia to spearhead the genomic NGCDS integration
research. These consortia consist of researchers from leading US hospitals and medical research
institutions. These consortia are tackling the clinical genomic integration problem from comple-
mentary angles as described below.
eMERGE: The collaboration between six medical US institutions called the Electronic Medical
Records and Genomics Network was formed in 2007. It was later expanded to 20 relevant groups
[3]. The network’s goal is to explore the integration of DNA repositories coupled to EHR systems
for advancing discovery in genome science. The eMERGE network has multiple objectives that
include use of EHR data for electronic phenotyping, conducting genome-wide association studies
using the phenotypes, return of results, integrating findings into EHR, and many others.
CSER: The Clinical Sequencing Exploratory Research (CSER) network was formed in 2011 to
examine the impact of genome-scale testing in diverse clinical settings. The CSER is a collabora-
tion of six US institutions, each having a site-specific workflow and its own knowledge base.
IGNITE: The Implementing Genomics in Practice Network (IGNITE) was formed in 2013 with
six initial sites. This project seeks to achieve several goals related to utilizing genomic analysis in
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clinical settings such as 1) expansion and linking of genomic medicine implementation efforts, 2)
development of new collaborative projects and methods for genomic medicine implementation in
diverse settings and populations, and 3) contributing to the evidence base of outcomes following
the use of genomic information for clinical care.
2.4 Conclusion
The road to personalized healthcare starts with integrating genomic data into the clinical pro-
cess. In this chapter, we identified the different aspects of genomic NGCDS integration. For each
aspect, we discussed the prominent genomic challenges and discussed possible resolution direc-
tions. Overall, the genomic NGCDS integration challenges require substantial innovations in the
bioinformatics infrastructure. In addition, more efforts are needed for developing high confidence
computationally driven methods to identify genomic variants and produce clinically actionable
conclusions. More attention should be geared towards training healthcare professionals on un-
derstanding and using genetic information. Finally, a parallel effort should be exerted to develop
interactive and rich clinical genomic outcome delivery methods to enable a better understanding
of genomic information.
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3. OVERCOMING THE GENOMIC DATA PROCESSING CHALLENGE: A CPU-GPU
ALGORITHM FOR PARALLEL READ ALIGNMENT
3.1 Introduction and literature review
Read alignment is one of the first stages in the processing of DNA raw data. In NGS, DNA se-
quences are broken down into small fragments which undergo wet-lab procedures to prepare them
for sequencing. The sequencing-ready fragments are then inserted into a sequencing platform,
which uses chemical and engineering methods to determine the nucleotide sequence of each frag-
ment [91]. The nucleotide sequence of a single fragment is called a read. NGS platforms typically
produce millions of read sequences (of sizes ranging from 25 to 400 bp) per run.
In the read alignment process, each read is aligned against the reference genome, in order to
find its mapping location(s) in the presence of genomic variations such as SNPs and Indels. The
presence of these variations in the genome and the reads adds more complexity to the alignment
process. NGS read alignment is one of the most time consuming stages in NGS preprocessing. This
stage could take up to 6 hours in aligning the genomic data of one patient on a modern machine.
This presents a serious computational bottleneck which could negatively impact the feasibility of
genomic NGCDS integration.
There are two main algorithms in the literature to perform NGS read alignment. The first
algorithm breaks down the genome into short sequences called k-mers and constructs a hash table
with their mapping locations. To align a read, the algorithm breaks it down to its k-mers and applies
the hashing function used for the genome to find the mapping location [92]. This strategy has been
used by the early generation aligners such as BLAST [93], MAQ [94], RMAP [95], BFAST [96],
and GSNAP GSNAP [97]. The second algorithm is adopted by most of the recent alignment tools
such as Bowtie [98] [99], SOAP2 [100], and BWA [101] [102]. The algorithm relies on a suffix
array representation of the genome based on Burrows-Wheeler Transform (BWT), combining this
Reprinted with permission from "A GPU-CPU heterogeneous algorithm for NGS read alignment" by Al Kawam,
Ahmad, Sunil Khatri, and Aniruddha Datta, 2018. International Journal of Computational Biology and Drug Design,
11, 1-2, c 2018 by Inderscience.
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with an indexing technique called FM-index [103]. BWTwas originally used as a text compression
algorithm. This algorithm transforms regular strings into ones containing long stretches of the
same character, in a lossless manner. Combined with FM-index, the algorithm is widely adopted
by the genomics community to develop efficient alignment techniques. The major advantages of
this approach include a low time complexity of O(n) to find an exact match where n is the length
of the read. The performance of the algorithm is independent of the size of the reference genome.
For that reason, BWT and FM-index has recently witnessed substantial adoption within alignment
tools.
The BWT string is calculated through the transform’s three steps: produce all rotations of the
inputted string, sort according to the first column, and finally store the last column. In order to
use FM-index to find a query string in a reference string, three components are needed. The first
component is the suffix array (SA) of the reference string. The second component represents the
occurrence table (Occ), which records how many instances of each character occur before every
index of the BWT string. And the third component, the C-string stores the location of the first
occurence of each character in the SA. The algorithm iterates while updating two values, Top and
Bottom. These values specify the range where the query string is found in the SA. The algorithm
terminates if the SA range becomes less than or equal to zero. The read alignment process of the
BWT algorithm with FM-index is illustrated through example in Figure 3.1.
In this example, the reference string is "CAGAGA". In a typical alignment application, this
reference string would be the genome string of the targeted species. We chose such a simple and
short reference to illustrate how the algorithm works. To find the BWT string for this reference,
every rotation of the reference string is calculated as shown in Figure 3.1a. Then, these rotations are
sorted alphabetically, with the string terminator ’$’ being the smallest lexicographically. Finally,
the last character in each rotation is stored to produce the resulting BWT string: AGGC$AA.
From the BWT string, two elements are created: The C-string will store the index of the first
occurrence of each unique character in the sorted list of rotated strings (i.e. 0 for A, 4 for C, 5
for G, and 0 for $). Occ records how many instances of each unique character exist before every
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index in the BWT string as shown in Figure 3.1b. Using the C-string and Occ, the algorithm finds
a substring through the procedure defined and described in Figure 3.1c.
To handle mismatches and gaps, the BWT with FM-index algorithm generally uses two main
methods. In the first method, if a mismatch is encountered, the algorithm tries substituting other
bases in the mismatch location and then chooses the base that extends the searched string the
farthest [101] [105]. The major shortcoming of this method is that it fails to account for gaps.
Due to this deficiency, most recent alignment tools have adopted a second method to account for
variations [98] [100]. The second method divides the alignment into two steps. In the first step,
the algorithm finds all the un-gapped matches between parts of the read and the genome. The
algorithm then groups colinear and close matches according to a score function which penalizes
the existence of a gap between the matches. Several variations of the second method exist in the
literature. Our algorithm adopts a variation of this method. In our variation the maximal exact
matches of different parts of the read are found in a first step and then stitched together using
dynamic programming in a second step. We selected this approach since it is most suited for GPU
based alignment, as we will describe in the following section. Furthermore, an extended discussion
on the NGS read alignment methods on both CPUs and GPUs is provided in [43].
In recent years, GPUs emerged as powerful and efficient computing platforms capable of
achieving significant speedups compared to typical computing machines. A GPU is a massively
parallel processor composed of several Streaming Multiprocessors capable of performing billions
of independent calculations per second. Although GPUs have been designed as graphics accel-
erators, they are being increasingly used for high-performance general non-graphics applications
due to their low cost and easy high performance. Another factor that has contributed to GPUs
popularity is the existence of parallel computing platforms such as CUDA [106], which have been
adapted to the GPU’s architecture. CUDA is a parallel computing platform and API model created
by NVIDIA. The CUDA platform is a software layer that gives direct access to the GPU’s virtual
instruction set and parallel computational elements, for the execution of several compute kernels
in parallel.
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The advantages of using GPU platforms over CPUs stem from several factors including:
 Specificity: GPU platforms are tuned to perform a specific task with high efficiency as op-
posed to the CPU which is designed to be a general purpose processor.
 Parallelism: Breaking up complex sequential computations into independent parts and si-
multaneously running these parts on several processors on the GPU results in large speedups.
GPU platforms exploit parallelism and often include a massive number of parallel proces-
sors.
 The GPUs use a Single Instruction Multiple Data computational model, in which the same
instruction is performed on different threads. This gives tremendous speedups for tasks that
require the same code to be run on multiple data objects. The read alignment task falls into
this category.
 Low memory latency: GPU platforms are designed to minimize memory latency. This is
achieved through enabling concurrent memory access from parallel processes. The following
realistic example illustrates this: Consider a type of process that involves a memory load
operation and then a computation. Also, consider that a memory load operation has a delay of
a 100 cycles while a computation operation only takes 1 cycle. If two similar but independent
processes A and B need to execute, the CPU would need a 100 cycles to load the data for
A, one cycle to compute for A, spend another 100 cycles to load the data for B, and then
compute B, thus spending 202 cycles in total. On the other hand, on a parallel processor
with concurrent memory access, the data for A and B can be loaded simultaneously and the
whole process would take 101 cycles to finish. The gains achieved by such a concurrent
memory access model are significant when there are more than 2 independent processes.
Only a few GPU-based read alignment implementations are found in the literature. One of
these implementations is SOAP3 [107] which is the GPU implementation of the sequential align-
ment algorithm SOAP2. SOAP3 was compared to Bowtie and BWA running sequentially on one
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thread. The speedups ranged between 3x and 29x (compared with a simple core implementation)
on different datasets. CUSHAW2-GPU [108] is the second version of the GPU-parallel CUSHAW
[109] alignment tool. This tool uses a strategy similar to BWA-SW which applies BWT with
FM-index to find exact matches, called seeds, then uses the Smith-Waterman algorithm to allow
for gaps. This implementation resulted in speedups ranging between 1.5x and 4x compared to
software tools such as Bowtie2, BWA-SW, and GEM. Finally, BarraCUDA [110] implemented a
BWT with FM-index strategy built on the foundation of BWA. The tool uses a Depth First Search
algorithm to find alignments of sequences M mismatches away from the read sequence. This
implementation was compared to BWA and the speedup achieved ranged between 2x and 6x for
different configurations.
In this chapter, we introduce a concurrent GPU-CPU alignment algorithm to perform gapped
read alignment. Our algorithm uses the hardware properties of the CPU and GPU to resolve the
main bottlenecks encountered in the alignment process. The algorithm implements a unique match
detection phase based on BWT with FM-index. The match detection strategy is tailored to im-
prove the throughput of the GPU. After that, the CPU and GPU work together to stitch the seeds,
accounting for mismatches and gaps. As the alignment process is applied on a batch of reads at
a time, the algorithm uses multiprocessing to concurrently load the reads of the next batch while
writing the results of the previous batch.
Our algorithm leverages the CPU and GPU capabilities to speed-up the alignment process using
the following techniques:
1. In the exact-match alignment process, our algorithm breaks up the read into several partitions
and assigns a GPU thread to each partition, thus increasing the number of active GPU threads
without increasing the per-read memory. Typical GPU alignment approaches assign one
GPU thread per read, which reduces the number of active threads due to memory limitations.
2. Implementing an advanced stitching technique to allow for gapped alignment. The stitching
is performed on both the CPU and GPU such that computationally expensive operations are
performed on the CPU, while the simple, and much more frequent, operations are performed
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on the GPU.
3. Taking advantage of parallel IO to read and write to the file system while the CPU-GPU
algorithm is computing the alignments.
The implementation details of these contributions are described in the next section.
3.2 Methods
Our algorithm utilizes both CUDA and OpenMP to exploit parallelism on both the CPU and
GPU platforms. Our algorithm first loads the BWT string into main memory, along with the
precomputed suffix array and sampled occurrence table. The algorithm then transfers the BWT
string and occurrence table to the GPU’s global memory. After that, the alignment algorithm
proceeds in a parallel pipeline composed of the three stages such that, once the pipeline is full,
all three stages work concurrently. In the first stage, a batch of reads is loaded from the disk and
transfered to the GPU memory in a single continuous block to minimize internal fragmentation.
In the second stage the reads are aligned to the genome in two phases whereas in the third stage
the alignment results are transfered back to main memory and are written to the output file. The
following section describes each of the steps performed in the pipeline.
3.2.1 GPU parallel alignment
After a batch of reads are loaded into the GPU’s global memory, the algorithm uses a parallel
implementation of BWT with FM-index, to concurrently align the batch of reads. According to
the BWT search algorithm, the match finding terminates when a mismatch is encountered. To get
around this, most tools replace the mismatching nucleotide with another nucleotide with the aim of
extending the alignment to cover as much of the read as possible. Although this technique works
very well in sequential tools, it might not be suitable for GPU implementation due to the compli-
cated control structures it needs. Due to their Single Instruction Multiple Data architecture, GPUs
achieve their highest speedups when they perform a simple control operation on many independent
instances. For that reason, our algorithm divides the alignment process into two phases: i) an exact
match search phase, referred to as seeding, and ii) a stitching phase. Both phases are designed to
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Figure 3.2: The parallel exact match search phase of our algorithm. Reprinted, with permission,
from [104].
have a simple control structure in order to utilize the GPU’s architecture.
3.2.1.1 Exact match search
Once the reads are transfered into the GPU, the exact match search kernel is launched. The
kernel threads are divided into blocks such that each block has its own shared memory. To achieve
maximum parallelism, the algorithm has to launch the largest number of concurrent threads possi-
ble. On the other hand, this number is limited by the amount of resources that could be allocated
to the threads, (shared memory in this case).
To achieve maximum speed and parallelism, the algorithm first copies the reads into the block’s
shared memory, which is about a hundred times faster than global memory. Second, the algorithm
assigns multiple GPU threads to align a single read, each starting at different read locations as
illustrated in Figure 3.2. We refer to the read segment aligned by each GPU thread as a partition.
The reasoning behind assigning several reads to the same read is as follows: Assigning one GPU
thread to a single read would limit the maximum number of concurrent threads to the number of
reads that could fit in shared memory. This number is usually much smaller than the number of
GPU threads that could be launched. Therefore, increasing the number of GPU threads per read
increases parallelism as long as the memory bandwidth doesn’t become a limiting factor (which we
insured). Another advantage of using this technique is that it offers an automatic way for detecting
mismatches and indels. The exact match alignment at each partition terminates when a mismatch
is encountered. Furthermore, each partition can have several exact matches in the genome. The
exact matches of each partition are represented as a suffix array interval bounded by the Top and
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Figure 3.3: The exact match stitching phase of our algorithm. Reprinted, with permission, from
[104].
Bottom values calculated using the algorithm in Figure 3.1. The suffix array intervals of all the
reads are then transfered back to main memory.
3.2.1.2 Stitching
The purpose of the stitching phase is to cluster and stitch together the exact matches produced
in the first phase, to produce the final alignment, as illustrated in Figure 3.3. The algorithm loops
through the the exact matches of each partition and uses the suffix array to find their possible
genomic mapping location. Concurrently, the algorithm divides the reads into two sets depending
on the number of matches of their partitions. If a read contains a partition with a number of
possible matches greater than a specified parameter, the read is labeled as Tough. The few Tough
reads undergo stitching on the CPU, whereas the rest of the reads are concurrently aligned on the
GPU. This technique preserves the simplicity of the control structures executed on the GPU and
hides the stitching time of the Tough reads (on the CPU) by stitching them in parallel with the GPU
reads. The stitching algorithm is a dynamic programming algorithm that calculates the alignment
location of a read in the presence of mismatches and gaps. Given a set of possible alignment
locations for each part of the read, the stitching algorithm produces a read mapping location that
minimizes the distances between the seeds. Furthermore, the stitching scoring function uses an
affine gap penalty to account for indels in the read. The algorithm stitches the regular reads on the
GPU using a separate thread for each read. The algorithm maximizes stitching speed by copying
the possible mapping locations of the reads and other frequently accessed variables into shared
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memory.The algorithm then copies back the alignment location of the GPU reads to main memory
and merges them with the mapping locations of the tough reads which were processed on the CPU.
3.2.2 CPU parallel alignment pipeline
After resolving the alignment bottleneck, the algorithm is faces another limiting factor for
its throughput. The reads to be aligned are loaded from the disk and after alignment they are
written back to the disk. Since disk access is generally slow, the read transfer operations hinder the
speedup achieved by accelerating the alignment phase on the GPU. To work around this problem,
our algorithm separates the reads into batches and divides the alignment process into 3 stages of
load (on the CPU), process (mostly on the GPU, as explained in section 3.1), and write back of
the results (on the CPU). The algorithm uses OpenMP to assign a unique thread to each stage
of the pipeline. Furthermore, we leverage the independence of these threads by overlapping the
three alignment stages. In other words, as the process stage is applied to a batch of reads, the
algorithm concurrently loads the reads of the next batch while writing the results of the previous
batch. Consequently, to achieve maximum throughput, the time taken by all three stages of the
algorithm should be equal to one another. This is achieved mainly by manipulating the size of
the batches to be loaded. An illustration of the pipeline, showing the overlapping stages, is shown
in Figure 3.4. It is worth mentioning that overlapping the disk read and write operations would
only work on systems with a parallel or distributed file system that allows reading and writing to
different files in parallel. On a typical desktop system with a local hard drive, the read and write
operations will be serialized by the operating system and thus no speedup will be produced due to
the overlapped IO feature.
3.3 Results
To evaluate the performance of our algorithm, we implemented it in C++ and used the OpenMP
and CUDA APIs to implement the CPU and GPU portions respectively. We ran the implemented
algorithm on an Intel i7-4790 3.6GHz system with 32GB DDR3 memory, with a TITAN X GPU
installed. The computer is connected to a parallel file system through network. We compared our
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Figure 3.4: The parallel alignment pipeline. Reprinted, with permission, from [104].
algorithm with BWA-mem v0.7.12 on several datasets as shown below. The BWA-mem tool ran
in the same system described above. We chose BWA-mem as a reference for comparison due to
its established reputation and wide adoption in the genomics community. Furthermore, it has been
recently used in several popular genomic analysis workflows such as Genome Analysis Toolkits’s
WGS analysis best practices workflow [44].
To evaluate the algorithm’s performance against other GPU-accelerated alignment algorithms,
we compared it with SOAP3-dp which one of the most well referenced GPU alignment tools. The
results of the comparison are also reported in this section.
3.3.1 Alignment accuracy
The speedups produced by using our accelerated algorithm should not be at the expense of
losing accuracy. Accuracy is a vital factor that could effect the downstream analysis of the genomic
data. For that reason, we compared our algorithm’s mapping accuracy with the widely used BWA-
mem alignment tool. For that purpose, we produced 1 million single ended reads of 100bp from the
Caenorhabditis Elegans genome (WS200.55, 102 million bp). The set of simulated reads have an
average of 3 mismatches per read. We created two sets of gapped and un-gapped reads to evaluate
the gapped-alignment capability of our algorithm. All reads in the gapped set contain a gap whose
length is pulled from a normal distribution N(500,30). As shown in Table 3.1, our algorithm had
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Table 3.1: The alignment accuracy on the gapped and un-gapped datasets. Reprinted, with permis-
sion, from [104].
BWA-mem Proposed Algorithm
Un-gapped Gapped Un-gapped Gapped
% Mapped 99.99 99.99 99.99 98.5
% Accuracy 94.63 82.04 94.86% 87.98
Table 3.2: The alignment time versus the number of threads per read increases. Reprinted, with
permission, from [104].
GPU Threads 2 4 8 16
Time (s) 2.73 2.83 3.67 7.67
a similar mapping percentage to BWA-mem for both gapped and un-gapped datasets. The two
algorithms had a similar percentage of correctly mapped reads from the un-gapped data set. The
distinction that arose between the two algorithms was in the percentage of correctly mapped reads
for the gapped dataset. Our algorithm achieved an 87.98% accuracy compared to BWA-mem’s
82.04%. This shows that our proposed algorithm not only preserves the alignment accuracy of
BWA-mem, but also improves upon it.
This improvement can be attributed to the nature of the algorithm. During the exact match
search phase several GPU threads are spread out across the read and independently attempt to align
the read from their starting points. The stitching phase then finds the location where most matches
align. With this strategy, increasing the number of GPU threads assigned to each read increases
the chance of it being aligned correctly. To verify this claim, we produced 6 simulated sets of
1 million 100bp reads each containing 0 to 5 mismatches respectively. As expected, Figure 3.5
shows that increasing the number of GPU threads per read results in a high alignment accuracy of
the algorithm, at the expense of a slight increase in alignment time (Table 3.2).
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Figure 3.5: The alignment accuracy versus the number of threads per read. Reprinted, with per-
mission, from [104].
3.3.2 Speedup
For most alignment algorithm, their speed changes depending on the number of mismatches
and gaps in the targeted reads. Consequently, to evaluate the speedup of our algorithm we produced
several sets of both gapped and un-gapped reads containing a different number of mismatches.
Again, we compared our results with BWA-mem and reported the results in Table 3.3. As could
be seen from the table, our algorithm achieved speedups reaching up to 22.3x compared to BWA-
mem running on one thread and up to 4.84x compared to BWA-mem running on 8 threads.
In addition, the table shows two desirable patterns. First, the speedup of our algorithm in-
creases as the number of mismatches increases for the reasons already discussed. The speedup
over BWA-mem increases 10.08% when the number of mismatches increases by one. Secondly,
the speedup for the gapped datasets was higher than that of the un-gapped datasets. The gapped
speedup exhibits an average of 11.53% increase over the un-gapped speedup. This information
shows that the strategy used in our algorithm resolves variations more efficiently than BWA-mem.
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Table 3.3: The speedup of the proposed algorithm compared to BWA-mem as the number of
mismatches increases on the gapped and un-gapped datasets. Reprinted, with permission, from
[104].
Mismatches 0 1 2 3
Un-gapped 1 Thread 11.15 16.93 18.21 22.33
8 Threads 2.47 3.83 4.09 4.84
Gapped 1 Thread 14.99 18.53 19.91 21.33
8 Threads 3.28 4.14 4.4 4.6
Figure 3.6: The speedup of the proposed algorithm compared to BWA-mem as the number of reads
increases. Reprinted, with permission, from [104].
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Table 3.4: The time of the proposed algorithm compared to BWA-mem and SOAP3-dp as the
number of mismatches increases on the 1M read dataset. Reprinted, with permission, from [104].
Time (seconds)
Mismatches 0 1 2 3
BWA-mem (1 Thread) 33.955 51.367 62.754 81.043
BWA-mem (8 Threads) 14.99 18.53 19.91 21.33
SOAP3 7.51 11.612 14.101 17.578
Our Algorithm 3.353 3.532 3.6525 3.776
3.3.3 Scalability
Finally, the scalability of the algorithm (as the number of reads increases) was assessed. Since
the complexity of the BWT with FM-index is O(n), the runtime of our algorithm is independent
of the reference size. Furthermore, the read length of NGS reads is typically fixed with an average
size of 100bp. Therefore, the primary scalability concern arises from the number of reads to be
aligned which usually varies between a few million reads to several tens of millions of reads. For
that purpose, we applied our algorithm to three sets of simulated reads with sizes 1, 10, and 100
million reads respectively. Figure 3.6 shows the speedup our algorithm achieved compared to
BWA-mem running on 1 and 8 threads. The results clearly show that our algorithm retains similar
speedups on all three datasets portraying the algorithm’s ability to scale elegantly as the number of
reads increase.
3.3.4 Comparison with SOAP3-dp
The main difference between our approach and SOAP3-dp is that our algorithm supports
gapped alignment while SOAP3-dp doesn’t. In addition, the results reported in Table 3.4 show
that our approach produces a better performance than SOAP3. This could be attributed to multiple
factors including the overlapped I/O, dividing each read to multiple partitions which are aligned in
parallel, and finally, the parallel stitching procedure.
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3.4 Conclusion
In this chapter, we introduced a concurrent GPU-CPU alignment algorithm to perform read
alignment based on BWT with FM-index. The algorithm uses the hardware properties of the
CPU and GPU to resolve the main bottlenecks encountered in the alignment process. The pro-
posed design exploits the GPU’s massive parallelism to hide memory access latency by aligning
hundreds of reads concurrently. Concurrent with GPU alignment, the algorithm uses the CPU’s
multiprocessing capability to load the next batch of reads and write the results of the previous
batch. We compared our tool with the BWA mem alignment tool and achieved speedups reaching
up to 28.12x. We demonstrated the algorithm’s ability to handle gapped and un-gapped alignment
efficiently for a varying number of mismatches. Finally, we demonstrated the algorithm’s ability
to scale as the number of reads increases. We hope that this work would present an algorithmic
model for the next generation of alignment algorithms.
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4. OVERCOMING THE STORAGE AND ACCESS CHALLENGE OF GENOMIC DATA:
GENOTYPE ENCODING USING SPARSE 2D BITMAPS
4.1 Introduction and literature review
After Read Alignment process described in the previous chapter, NGS data undergoes genotyp-
ing. Genotyping is the process of determining the values of the genetic variations (genotypes) that
occur between individuals in a certain cohort or population. Genetic variations can contribute di-
rectly or indirectly to the development of many phenotypic traits including diseases such as cancer.
Genetic variations could occur in the genome in several forms, including SNPs and Indels [13].
SNPs, as described in previous chapters, are differences of one nucleotide base between the target
and reference sequences. SNPs represent the most common type of variation in human genomes
and are estimated to account for 90% of all sequence variation [111]. It is also estimated that there
are 10 to 30 million SNPs in humans, occurring on average about every 100 to 300 bases. Conse-
quently, information about SNPs constitutes the majority of the massive amount of data produced
in genotyping studies.
The wide adoption and utilization of genotype information in genomic studies prompts the
development of efficient data storage and access methods. Most current methods rely heavily on
text files to store, retrieve, and transport their data. Genotype information is stored in VCF [112]
text files. Each row in a VCF file represents a SNP, specified by its chromosomal location and a
zero or one genotype value for each sample in the studied cohort or population. A value of zero
represents that a reference allele is present in the sample whereas a value of one represents that the
alternate allele is present. Since humans are diploid organisms, two values are reported for each
sample.
Recently, there has been increasing interest in adopting a database representation for genotype
information. This interest stems from the need for integrating multiple applications and enabling
 c 2018 IEEE. Reprinted, with permission, from Al Kawam, Ahmad, and Aniruddha Datta, "Fast and efficient
genotype encoding using sparse 2D bitmaps for database-driven genomics applications", 2018 IEEE EMBS Interna-
tional Conference on Biomedical and Health Informatics, 2018.
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communication between them under time-critical settings. Adopting a database representation is
particularly important for developing genomic web applications such as genome browsers such as
the human genome browser and the Integrative Genomics Viewer. It is also essential for develop-
ing SOA genomics frameworks such as Galaxy [113]. Furthermore, database genotype represen-
tations are needed to drive clinical genomic applications which generally use standardized query
languages such as SQL for integrating genomic and healthcare applications [7] [8].
These applications often access large-scale genotype data in their analysis pipelines and there-
fore would benefit from a database representation to facilitate their operation. To achieve that
purpose, several conceptual modeling approaches have been proposed in the literature which use
entity relationship models to represent the different relationships within genomic data including
genotype information [114, 115, 116, 117]. However, due to the massive scale of genotype infor-
mation, database-driven genotype representations face serious space and access time challenges.
EVD [117] is a well-established database representation for storing genotype data. EVD en-
ables the efficient representation of large-scale genotype data and allows for fast access to these
genotypes through a specialized API. EVD is used by the Ensembl genotype browser to display
1000 Genomes genotypes on its genome tracks. EVD divides the genome of each sample in the
1000 Genome project into regions and then uses Perl’s pack method to compress genotype data
occurring in that region, as illustrated in [117]. The compressed data is then stored as a separate
entry in an SQL database. This representation was able to significantly decrease the storage re-
quirements of the 1000 Genomes data. However, as we show in this chapter, there is still room
for improved database representations of genotyping data. In this chapter we propose a genotype
database representation strategy which provides further access speedups and compression ratios.
Guided by the unique nature of genotype data, and inspired by the advances in digital image
compression algorithms, we propose a method to improve upon EVD’s genotype representation.
We show that replacing EVD’s generic compression algorithm with an algorithm specifically de-
signed to operate on genotype data can result in significant reductions in the storage requirements
for large-scale genotype information.
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Figure 4.1: An example of the 2D bitmap genotype representation. Reprinted, with permission,
from [118]. c 2018 IEEE.
In this chapter we describe the design and implementation of our genotype database approach.
According to this technique, we represent the patients genomes as 2D bitmaps. A bitmap is a type
of memory organization used to store digital images. The term bitmap refers to the collection of
bits, where each bit is set to either a zero or a one according to predefined strategy. Similar to
EVD, in our approach, we break up the patient’s genome into continuous regions, each containing
a fixed number of DNA nucleotides . These genomic regions will represent the rows of the 2D
bitmap. The DNA nucleotides in each region will represent the cells of each row as illustrated
in Figure. 4.1. Since we are only know the genotype value of the nucleotides overlap with SNP
locations, the rest of the genotype values are left blank. The sparse nature of SNPs enables our
2D bitmap representation to achieve a high level of compressibility, which significantly reduces
storage requirements.
4.2 Methods
4.2.1 General genotype representation
From a memory perspective, each genotype value can be represented using a single byte of
memory , comprising of eight binary bits. However, since the DNA alphabet is only composed of
4 characters, the most efficient representation could be achieved through using 2 bits per DNA base,
hence reducing the storage requirement by a factor of 4. More specifically, in our representation
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we assign the values 00, 01, 10, and 11 to A, C, G, and T respectively. This 2-bit encoding
is often used for storing large genome files in popular repositories such as the UCSC Genome
Browser [119], and Ensembl [120]. We utilize 2-bit encoding to generate a binary version of our
2D genotype bitmap. The resulting 2D bitmap representation offers several advantages that reduce
storage space and facilitate access. These advantages include:
1. Direct access: the exact location of a given SNP in the bitmap can be easily calculated and
its genotype value could be retrieved in one memory access.
2. Compact representation: using only 2 bits to represent the genotype value of a SNP reduces
the storage size required to represent all locations by a factor of 4.
3. High compressibility: although a patient can have millions of SNPs, these actually represent
a tiny fraction of the entire genome. The important consequence of this fact is that most
of the locations in the bitmap will be zeros. This type of bitmaps is referred to as a sparse
bitmap, which is characterized by a high compressibility.
Following these properties, a SNP’s location in the bitmap, given its chromosomal location, can be
easily calculated in two steps, as follows:
1. Determining the SNP’s row number could be achieved through dividing its chromosomal
location by the number of nucleotides per row, which is a predefined number. From a
memory perspective, if 256KBs are allocated to each row in the bitmap, it follows that
256x1024x4=1,048,576 nucleotides could be represented in that row. The expression to
calculate the row number is given in Eq. 4.1, where LC is the chromosomal location of the
SNP, GPR = GPB NB is the number of nucleotides per row, GPB = 4 is the number of
nucleotides per byte and NB is the number of bytes allocated to the row.
Row Number =
LC
GPR
(4.1)
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2. Determining the SNP’s column number on the other hand requires two operations: a) calcu-
lating the byte number in the row where the SNP is located, and b) determining the SNP’s
location in the byte itself. These values could be calculated using equations Eq. 4.2 and Eq.
4.3, wheremod is the modulus operator.
Byte Number =
mod(LC ; GPR)
GPB
(4.2)
Location in Byte =
mod(mod(LC ; GPR); GPB)
(4.3)
4.2.2 Unknown genotype representation
Genotyping experiments aim to determine the genotype value of SNPs, which are widely dis-
persed across the genome. As a consequence, only the genotype values at these locations will be
known, leaving the value at most of the other nucleotides unknown. This property of genotyping
results in the sparseness demonstrated in Figure 4.1. However, this also creates a problem for
the 2-bit encoding strategy by introducing a fifth possible value to be represented, the ’Unknown
Genotype’. Representing five values using a binary representation requires 3 bits which is prob-
lematic on two fronts. On one front, this reduces the representation utilization of our method. A
3-bit representation is capable of representing 8 values. However, we would only use 5 of these
values, therefore decreasing the representation utilization from 100% to 62.5%. The second prob-
lem we face by adopting a 3-bit encoding would be losing the compact representation we achieve
using a 2-bit representation. A byte is capable of storing four 2-bit values. However, if a 3-bit
representation is used, we are faced with two options, storing two 3-bit genotypes in a byte and
either a) splitting the third genotype between the current and next byte, or b) leaving the last two
bits of the byte unused. The first option introduces significant complications in determining the
genotype’s location when the genotype’s value needs to be accessed. The second option preserves
simple direct access at the expense of less memory utilization. However, neither options preserve
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the simplicity and efficiency of using a 2-bit representation.
In order to avoid using the wasteful 3-bit representation, we create two 2D bitmaps: the first
bitmap is a standard 2-bit representation of the nucleotides. The second bitmap is a bitmask where
each bit corresponds to a location in the genome. That is, if a bits value is 1, this means that the
corresponding genomic location contains genotype information. Having a 0 in a location would
mean that the genotype information is unknown. Since each bit represents a genomic location,
each byte in the bitmask can encode for eight locations thus achieving a very efficient and compact
representation. Furthermore, due to the relatively low frequency of SNPs in the genome, this
results in a sparse bitmask, which is highly compressible. These properties enable storing the
bitmask with minimum size overhead.
4.2.3 Diploid genotype representation
Since humans are diploid organisms, each genotype contains the value of two nucleotides. To
account for diploidy in our bitmap representation, we considered two methods. The first method
constructs a separate bitmap for the genotype value on each chromosome. The second method
stores both values of the genotype consecutively in one bitmap. Since both nucleotides of a geno-
type have the same the known/unknown status, the two studied methods require the construction
of a single bitmask. Although both methods require the same memory size, the second method
yielded better access times. This could be attributed to the difference in genotype retrieval be-
tween the two methods. When a genotype value is queried, the first method retrieves two separate
and non-consecutive bytes to recover the nucleotide values. The second method however, only re-
trieves one byte which contains both nucleotide values and therefore avoiding access delays. Using
the second method however requires the GPB variable in Eqs.4.1,4.2& 4.3 to be set to two.
4.2.4 Compression strategy
One of the most important advantages of using bitmaps is their high compressibility rates.
The optimal compressibility could be achieved by compressing the entire 2D bitmap. However,
compressing the entire bitmap introduces SNP access delays. When a SNP is queried, the entire
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bitmap will have to be retrieved and uncompressed to determine the genotype value. This could
cause impractical delays for time-critical applications such as web-based browsers and analysis
tools. To overcome this, we compressed each row in the bitmap separately. When a genomic
location is queried, its row value in the bitmap is easily be calculated. The compressed genomic
row is then retrieved and decompressed efficiently.
The bitmap and bitmask arrays created by our approach are highly compressible due to their
sparsity. Our approach uses the DEFLATE [121] algorithm to compress the genomic regions and
the bitmask arrays. This algorithm uses a combination of the LZ77 [122] and Huffman coding
[123] algorithms to achieve high compression ratios while maintaining fast compression/decompression
times.
4.3 Results
We conducted a series of three experiments to evaluate the different aspects of our method
and to compare it with the database representation of EVD. In the first experiment, we varied the
size of the genomic regions that form the rows of our 2D bitmap and observed how the storage
requirements and access time of our approach varied. In the second experiment, we compared
our approach to a baseline approach and to the EVD approach for a range of genotyping densities
and observed both storage and access time requirements. In both of these experiments we used a
simulated genome of 100 million bases. The baseline approach stores the SNPs of each individual
as separate database entries. This baseline allows us to assess the benefits of using our compression
method by comparing it to a method that does not use compression. In the third experiment, we
compared the three approaches on a real dataset extracted from the 1000 Genomes project.
We conducted our experiments on a core i7 system with 32GB of memory. We used Mysql as
our database system, since it is used by EVD system. We implemented our encoding algorithm
and all the procedures of the following experiments using Python scripts.
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Figure 4.2: The database access time for our bitmap approach as region size (row size) varies.
Reprinted, with permission, from [118]. c 2018 IEEE.
4.3.1 Storage requirements and access time vs region size
In the first experiment, we varied the size of the genomic region represented as a row in our
2D bitmap and observed its effect on the storage requirements and access time. The purpose of
this experiment to To find the best configuration for our approach which occurs at a trade-off
between region size and access time. We used a simulated genome composed of 100M bases with
an average distance between consecutive SNPs equal to 150 nucleotides. We varied the genomic
region size between 50 thousand bases and 3 million. The results obtained are summarized in
Figure 4.2 and Figure 4.3. As expected, the database size decreased as the region size increases.
This is attributed to the fact that as the region size increases, the number of entries in the database
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Figure 4.3: The database Size for our bitmap approach as region size (row size) varies. Reprinted,
with permission, from [118]. c 2018 IEEE.
decreases. Furthermore, at each entry, the compression algorithm will produce a more efficient
compression of the bitmap row as its size increases. On the other hand, the access time did not
decrease monotonically as region size increased. For a small region size, the database access time
was high due to the existence of a large number of entries. As the region size increased, the
number of database entries decreased and with it the access time decreased as well. The decrease
in access time came to a halt and started increasing when the region size became relatively large.
This is attributed to two delays: i) the delay imposed by the retrieval of the large string in the each
entry and ii) the overhead of decompressing the retrieved string which increases as the size of the
string increases. According to these results, our approach can work efficiently for a wide range of
region sizes. Using both figures, a value for region size could be selected by choosing a value that
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Figure 4.4: The compression and speedup achieved by our bitmap algorithm as compared to a
baseline database implementation. Reprinted, with permission, from [118]. c 2018 IEEE.
minimizes database size while yielding an acceptable access time. In this particular case, we chose
the region size value of 480K nucleotides.
4.3.2 Storage requirements and access time vs SNP density
In the second experiment, we evaluated our approach as we varied the average distance between
two consecutive SNPs. We compared the database size and access time we achieved using our ap-
proach to the corresponding values achieved using a baseline approach and EVD’s approach.As
explained earlier, the baseline approach stores the SNPs of each individual as separate database
entries, which is beneficial for obtaining a reference for comparison between different methods.
The results of the comparison between our method and the baseline approach are summarized in
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Figure 4.4. Our approach achieved significant compression ratios, reducing the database size by an
average of 91%. Our approach also resulted in speed-ups in access time reaching up to 540 times.
Furthermore,a notable advantage of our approach is that both compression ratios and speedups
increased as SNP density increased which makes this approach suitable for dense genotyping ap-
plications. This property of our approach gave it an edge over EVD’s approach as shown in Figure
4.5. As SNP density increased, our algorithm was able to make substantial reduction in database
sizes as compared to EVD’s results reaching up to 47.33% in the high SNP density dataset.
4.3.3 Storage requirements and access time on a real dataset
To evaluate our approach’s performance on real datasets, we used to represent the pilot data
of the 1000 Genomes Project. The dataset contains 14.8 million SNPs for 179 individuals from 4
different populations. We compared our approach to the baseline approach and EVD’s approach.
Our approach was able to store the entire dataset in 4.752GB as opposed to the 45.24GB needed
by the baseline approach and the 6.37GB needed by EVD’s approach. Furthermore, our approach
was able to achieve this compact representation while maintaining the same average access time
as EVD, which was around 100 times faster than that of the baseline approach.
4.4 Conclusion
In this chapter we introduced a genotype encoding technique based on 2D sparse bitmaps
designed to achieve high compressibility while minimizing access time. Using this approach, we
were able to reduce the SNP storage space to 10.5% of its original size while achieving a 100
fold speedup. Furthermore, we compared our approach to the genotype encoding of the popular
Ensembl Variant Database and achieved database size reductions reaching up to 47.33% without
compromising access time. We believe that the proposed method could enable genomic NGCDS
integration through incorporating the 2D bitmap representation into common genotype analysis
and visualization applications.
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Figure 4.5: A comparison of database size between our bitmap approach and EVD’s approach.
Reprinted, with permission, from [118]. c 2018 IEEE.
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5. OVERCOMING THE MISSING DATA CHALLENGE OF ELECTRONIC HEALTH
RECORDS: A PROBABILISTIC APPROACH TO DISEASE RISK ESTIMATION
5.1 Introduction and literature review
Over the past decade, EHRs have transformed the practices of healthcare delivery and have
shown significant promise for improving care quality [1, 2]. Due to initiatives such as the $19
billion HITECH act in the US, EHR systems are now available in most clinics and healthcare
provider facilities across the country. For example, in 2008, only 38.4% of office-based physicians
reported using EHR systems. This number has risen to 78% by 2013 and as of 2014, more than
80% of physicians have adopted some form of EHR system [124].
EHRs store various forms of data that capture the different aspects of clinical care includ-
ing diagnosis, medical procedures, prescribed medication, laboratory test results and radiological
imaging data in addition to the traditional clinical narrative. Comprehensive EHR data are usually
coupled with analytics and data mining tools to empower patient-centered CDS [1]. In order to
generate personalized medical recommendations, EHR-empowered CDS systems often utilize dis-
ease risk assessment models to evaluate the patient’s current and future risk of contracting a certain
disease such as cancer, diabetes, or heart failure[9]. The medical literature provides a large number
of established and verified disease risk models [125, 126, 127, 128, 129]. However, disease risk
assessment models are usually presented in the form of online or paper questionnaires and cannot
be directly applied to EHR data.
In the past few years, there have been several attempts to implement EHR-based risk assess-
ment models [124, 10, 11, 12, 130, 131, 132, 133, 134, 135, 136]. We can divide these EHR-risk
assessment models into two types based on their design: the first type creates a mapping between
EHR fields and the elements of an established risk assessment model and then uses that model to
produce a risk score [124, 131, 132, 133, 134, 135, 136]. The second type uses machine-learning
algorithms that utilize temporal EHR data. These algorithms use EHR data trajectories of patients
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that have developed the disease to learn a risk assessment model that could be applied to other pa-
tient trajectories in order to predict their disease risk [10, 11, 12, 130]. EHR-based risk assessment
models could be applied to either structured EHR data or unstructured EHR data in the form of
clinical narratives. In the latter case, Natural Language Processing algorithms are used to extract
the relevant medical information that is used in the risk assessment [10, 12, 135].
EHR-based methods face a major challenge that could limit their applicability. This limitation
stems from the unavoidable fact that EHR records are often incomplete and typically include a
large amount of missing data [10, 11, 12]. The missing data in an EHR could be of three types:
1. The data could be missing completely at random. In that case, the reason for a missing entry
at variable, Y , has no relation to the actual value of Y . For example, a patient could be
missing a weight measurement because the scale was broken at the time of the visit.
2. The data could be not missing at random. This occurs when the reason for a missing entry
at variable Y is directly related to the value of Y . For example, multiple studies [137, 138]
have shown that patients from ethnic minority groups are less likely to report information
about their race and ethnicity.
3. The third type of missing data is missing at random . This occurs when the reason for a
missing entry at a variable Y is not directly related to the value of Y , but is related to the
value of another variable Z. This type of missing data represents the majority of missing data
entries where Z represents the patient’s medical condition during the healthcare visit. Each
EHR entry will mainly consist of the medical information that is relevant to the patient’s
condition at that particular visit. Therefore, a patient might be missing a cholesterol level
measurement if the reason for the visit was unrelated to blood pressure.
Most EHR-based risk assessment models proposed to date do not account for missing data
in numerical EHR fields, such as lab results and vital signals information [10, 11, 12, 130, 131,
132, 133, 134]. These methods either delete the records having missing data entries or limit their
analysis to International Classification of Disease (ICD) codes. In such a case, a missing ICD
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value is assumed to be equivalent to the absence of the condition. Deleting entries with missing
numerical field data limits the applicability of EHR-based risk assessment models to the cases
where all the information required by the model are available for the same entry.
In a recent study Jonnagaddala et al. [135] showed that EHR-based risk assessment models
could utilize imputation strategies typically used in standard risk assessment models [139, 140,
141]. In that study, the authors used three common imputation strategies: substituting the missing
data with the mean value of the available data, single value imputation using linear regression,
and Multiple Imputations by Chained Equations (MICE) [142]. MICE creates several versions of
the dataset, each with different imputed values resulting from different regressions. The resulting
imputed values are then merged to form the final values. The results showed that imputation could
be used to calculate acceptable risk assessment estimates for patients with missing data.
Due to the high impact that EHR-based disease risk assessment models could have on health-
care quality, and because of the lack of EHR-specific imputation techniques, we carry out this
investigation which aims to perform disease risk assessment from incomplete EHR records. We
focus our study on EHR records that have missing data in their numerical fields, such as lab test
results and vital sign values. We choose coronary artery disease to be our target disease. The main
reason behind our choice is that the CAD risk assessment models found in the literature are well
established and verified.
Coronary artery disease is a leading cause of death in the United States and across the world
[143, 144]. CAD occurs due to accumulating plaque in the coronary arteries which might cause se-
vere blockage and could ultimately lead to myocardial infarction. CAD incidence rates are increas-
ing annually making CAD the most common type of heart disease among the general population
[145]. CAD management costs create an enormous burden on the healthcare system. The develop-
ment of advanced CAD prediction and detection techniques could alleviate some of the morbidity
and financial burdens of this disease by enabling early intervention and prompting lifestyle changes
[145, 146, 147].
We evaluate the performance of the imputation methods described above under various types
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Table 5.1: The Framingham risk factors and their respective EHR sources.
Risk Factor Possible Values EHR Source
Age 30-74 Patient Info
Gender M/F Patient Info
Total Cholesterol 206-284 Lab Test Result
Low-density lipoproteins
cholesterol
130-194 Lab Test Result
High-density lipoproteins
cholesterol
M: 28-72 / F: 34-83 Lab Test Result
Systolic blood pressure M: 102-152 / F: 96-160 Vital Sign Measurement
Diastolic blood pressure M: 53-91 / F: 52-88 Vital Sign Measurement
Smoking history Y/N Patient Info
Diabetes history Y/N Diagnosis Codes
and levels of missing data. We then introduce a probabilistic strategy for performing EHR-based
CAD risk assessment in the presence of missing data. The proposed model combines probability
distribution analysis, mixed-effects linear modeling, and Bayesian updating to produce an accurate
CAD risk assessment. This risk estimation strategy has three main characteristics: (i) dynamic:
the model undergoes updates as new data is made available, (ii) population specific: the model is
driven by EHR data and therefore it inherently accounts for the characteristics of the EHR patient
population. (iii) patient-level: the model produces CAD risk assessment score for each patient in
the EHR meeting the model’s basic requirements. We demonstrate that our method significantly
outperforms competing EHR-based CAD risk estimation strategies.
5.2 Methods
In this section, we provide a detailed description of our CAD risk estimation strategy and the
techniques used in its implementation. Furthermore, we describe the dataset we used to design our
strategy and the CAD risk assessment model below.
5.2.1 MIMIC-III EHR Datasets
The EHR datasets used in this study were acquired from the Medical Information Mart for In-
tensive Care III (MIMIC-III) database [148] which contains the de-identified EHR data of patients
63
who stayed at the critical care units of the Beth Israel Deaconess Medical Center between 2001
and 2012.
In total, the dataset contains 58,976 admission records collected from 46,520 patients. Each
record contains detailed health-related information including: (i) information about the patient
such as date of birth, gender, ethnicity, and smoking status, (ii) ICD9 diagnosis codes and Common
Procedure Coding (CPT) procedure codes, (iii) Lab test results, imaging reports, and vital sign
measurements, and finally (iv) medications and dosage information.
Throughout the chapter, we utilize the fields and records of this EHR to carryout the different
experiments, as reported in the Results section.
5.2.2 Framingham risk score
CAD risk assessment is usually carried out using scoring systems, which are numerical mod-
els used to calculate the probability of a patient developing CAD within a ten year period. The
Framingham risk score (FRS) [149] is one of the most well-accepted and widely adopted scoring
systems. FRS was developed as part of the Framingham heart study which is an ongoing long-term
cardiovascular study that began in 1948 and included more than five thousand adult subjects. The
resulting CAD risk assessment scoring system calculates the probability of individuals aged 30-74
years to develop CAD within 10 years.
FRS calculation is based on the following risk factors (RFs): age, gender, total cholesterol
(TCL) for female patients, or low-density lipoproteins cholesterol (LDL) for male patients, high-
density lipoproteins cholesterol (HDL), systolic blood pressure (SBP), diastolic blood pressure
(DBP), diabetes history and smoking history. Further information of the FRS risk factors is pro-
vided in Table 5.1 which was constructed based on information extracted from [150] and [151].
The smoking history and diabetes history risk factors are presented in the form of a binary field.
If the patient has a smoking or diabetes history, a number of risk points are added to the patient’s
points total. The remaining risk factors are presented as non-overlapping consecutive ranges of
each risk factor’s values. Each value range is assigned a discrete number of points corresponding
to the risk it causes. The number of points assigned to each range differs depending on the gender
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Table 5.2: The FRS value of the age risk factor.
Age
Men Women
Years Points Years Points
30-34 -1 30-34 -9
35-39 0 35-39 -4
40-44 1 40-44 0
45-49 2 45-49 3
50-54 3 50-54 6
55-59 4 55-59 7
60-64 5 60+ 8
65-69 6
70-74 7
Table 5.3: The FRS value of the cholesterol-related risk factors.
LDL - Cholesterol Total Cholesterol HDL - Cholesterol
Men Women Men Women
mg/dl Points mg/dl Points mg/dl Points mg/dl Points
<100 -3 <160 -2 <35 2 <35 5
100-129 0 160-199 0 35-44 1 35-44 2
130-159 0 200-239 1 45-49 0 45-49 1
160-189 1 240-279 1 50-59 0 50-59 0
190 2 >280 3 60 -1 >60 -3
of the patient. After determining the number of points for each category, the points are added
together to produce the points total. Finally, the points total is converted, according to gender, to
a risk score representing the probability of the patient developing CAD in a 10-year span. This is
illustrated in Tables 5.2-5.6. The FRS then categorizes the patient into one of three risk intervals,
according to the risk score. The patient is considered to have a low risk if the score was below
10%, a medium risk if the score was below 20% and a high risk otherwise.
5.2.3 Framingham risk score from EHR Data
The FRS risk factors can be easily extracted from EHR data (See Table 5.1). For a particular
EHR entry, age is the difference between the admission date and the patient’s date of birth. Gender
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Table 5.4: The FRS value of the blood pressure-related risk factors.
Blood Pressure
Men
Systolic Diastolic(mmHg)
(mmHg) <80 80-84 85-89 90-99 100
<120 0 0 1 2 3
120-129 0 0 1 2 3
130-139 1 1 1 2 3
140-159 2 2 2 2 3
160 3 3 3 3 3
Women
Systolic Diastolic(mmHg)
(mmHg) <80 80-84 85-89 90-99 100
<120 -3 0 0 2 3
120-129 0 0 0 2 3
130-139 0 0 0 2 3
140-159 2 2 2 2 3
160 3 3 3 3 3
Table 5.5: The FRS value of the other risk factors.
Other Factors
Men Women
Diabetes 2 4
Smoker 2 2
and smoking status are directly reported in the EHR. Systolic and diastolic blood pressures are
vital sign measurements which are reported as chart events in the EHR. TCL, HDL, and LDL are
all lab test results which are usually reported in the EHR during the patient’s stay. Finally, since
personal diabetes history is not directly reported in the EHR, it can be inferred by checking if a
diabetes diagnosis ICD9 code is present in the EHR entry, or in any previous entry belonging to
the same patient.
Since the target of this study is EHR numerical fields, we assumes that age, gender, and smok-
ing history are not subject to having missing data. Following our definition of diabetes history, we
assume that this risk factor field is not subject to having missing data either. In other words, if a
66
Table 5.6: The FRS 10-year CAD risk probabilities.
10-year CAD Risk
Men Women
Points Total 10-Year Risk Points Total 10-Year Risk
-3 1% -2 1%
-2 2% -1 2%
-1 2% 0 2%
0 3% 1 2%
1 4% 2 3%
2 4% 3 3%
3 6% 4 4%
4 7% 5 4%
5 9% 6 5%
6 11% 7 6%
7 14% 8 7%
8 18% 9 8%
9 22% 10 10%
10 27% 11 11%
11 33% 12 13%
12 40% 13 15%
13 47% 14 18%
14 56% 15 20%
16 24%
17 27%
diabetes ICD9 code is not found in any of the current and previous entries, it is assumed that the
patient does not have an apparent history of diabetes.
In our analysis, we extracted the complete entries which do not contain any missing FRS values
from the MIMIC-III EHR. We limited our study to the patients whose ages ranged between 30
and 74 years in order to be in agreement with the FRS constraints. This resulted in a total of
1146 entries which we henceforth refer to as Complete records. In the remaining records, we
made the following observations: when a blood-pressure measurement is missing (DBP or SBP),
both measurements would be missing. Similarly, if a cholesterol measurement is missing (HDL,
LDL, or TCL), all cholesterol fields would be missing. Therefore, when studying missing data
effects, we can cluster both blood pressure measurements together in one group and all cholesterol
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measurements together in another group. We extracted all entries that have both blood pressure
values and no cholesterol values. We will refer to this data as BP-Only records. Similarly, we
extracted the records that have complete cholesterol values and no blood pressure values. We refer
to this dataset as CHL-Only records. Finally, we extracted the records that have neither blood
pressure nor cholesterol data. We refer to these records as Basic-Info records. We report the
statistics of these categories in Figure 5.1.
Using the above type definitions, the results show that Complete records have by far, the small-
est number of entries in the EHR. BP-Only and CHL-Only missing data patterns are present in
about 50% of the total records whereas Basic-Info records constitute about 46% of the total records.
The statistics of Figure 5.1 highlight the limited applicability of current EHR-based risk as-
sessment methods that account only for Complete records. Consequently, these risk assessment
methods can only be applicable to about 4% of the total entries found in the EHR. The abundance
of missing values presents challenges to standard imputation techniques and creates a strong moti-
vation for developing advanced methods that accurately estimate CAD risk in the presence of these
types of missing values.
5.2.4 Probabilistic risk estimation
In this section, we present a probabilistic strategy that aims to accurately estimate the CAD
risk for patient records having missing values in their numeric data fields (cholesterol and/or blood
pressure fields). For a given risk factor, our strategy uses existing EHR records to fit a normal
distribution to find the possible values of that risk factor. We then map the possible FRS scores of
that risk factor to the probability distribution to calculate a probability value for each risk score.
By combining the values and probabilities from different risk factors, our method produces a prob-
abilistic distribution for the total risk score. The mapping is achieved through the procedure de-
scribed in this section.
For a certain patient in the EHR, consider that the patient has a risk factor x with missing
values. Furthermore, consider that x is not associated with any other risk factors. In our method, we
assume that the values of x follow a normal distribution whose probability density function (PDF)
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Figure 5.1: The number of records found in the EHR for each type of missing data.
is denoted by f(x). At a population level, cholesterol levels and blood pressure measurements can
be assumed to follow a normal distribution [150, 151, 152]. We further verified that this assumption
in our EHR data. Following this assumption, we can use the probability distribution of risk factor
values to calculate the corresponding risk score probability distribution.
FRS assigns a finite set of risk scores to each risk factor. The risk factor values are mapped to
these risk scores using the mapping described in [153]. In probabilistic settings, this translates to a
transformation from a normally distributed risk factor value into a discrete random variable (DRV)
representing the risk scores. Consequently, each risk score has a probability calculated from the
normal distribution’s pdf using the following formulation:
Consider the DRV Z representing the point scores of a risk factor and fz1; z2; :::; zi; :::; zng, the
set of possible point scores of Z. The probability of obtaining a certain point score is calculated as
follows:
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P (Z = zi) =
Z U(zi)
L(zi)
f(x)dx (5.1)
where,
x  N(x; x) (5.2)
U(zi) and L(zi) are the boundaries of risk factor ranges associated with each risk score as given
in [153].
The points total can then be calculated by adding the DRVs of the missing risk factor values
with the points of the known risk factor values. This results in a DRV representing the possible
values for the points total, and their probabilities. Finally, the FRS 10-year risk can be calculated
by mapping each possible points total value to its corresponding FRS risk score.
Example: Assume a male patient’s record is missing both LDL and HDL measurements. In
order to calculate the FRS points total, we must first calculate the discrete probability distribution
for the values of each of the missing risk factors. The point score for the LDL can take four values:
{-3, 0, 1, 2}, as shown in Table 5.3. The probabilities of these outcomes are calculated as follows:
P (ZLDL =  3) =
Z 100
  inf
f(x)dx
P (ZLDL = 0) =
Z 160
100
f(x)dx
P (ZLDL = 1) =
Z 190
160
f(x)dx
P (ZLDL = 2) =
Z inf
190
f(x)dx
(5.3)
where f(x) is the pdf of x  N(LDL; LDL). The mean LDL value, LDL, and its standard
deviation, LDL are calculated using the procedure detailed later in this section.
Similarly for HDL, ZHDL can take one of four values: {2,1,0,-1} whose probabilities are cal-
culated using the PDF of x  N(HDL; HDL). Assuming that the record belongs to a male
patient who is 60 years of age, with neither a smoking history nor a history of diabetes, and having
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135mmHg and 87mmHg for his SBP and DBP respectively, the FRS points total for that patient
will be a DRV, ZPT having the following possible values: {2, 3, 4, 5, 6, 7, 8, 9, 10}. As explained
earlier, the total score, ZPT , can be calculated by extracting the relevant values from Tables 5.2,
5.3, and 5.5, then adding their sum to ZLDL and ZHDL. Since ZLDL and ZHDL are DRVs, the
probabilities of ZPT ’s outcomes can be calculated using the formula given in Eq. 5.4.
P (Z = z) = P (X + Y = z)
=
X
y
P (X = z   y)P (Y = y)
(5.4)
Finally, the FRS risk probability can be calculated by mapping the total risk score to relevant
value in Table 5.6. Consequently, the patient in our example will have the following possible risk
values: { 4%, 6%, 7%, 9%, 11%, 14%, 18%, 22%, 27%}. These probabilities are driven by the
values of the known risk factors and the probability distribution of the unknown risk factors in the
local EHR. For example, assuming LDL = 82, LDL = 31, HDL = 41, and HDL = 14, the RFS
risk score distribution has an expected value of 8.9% as shown in Figure 5.2. It is clear from the
figure that the risk score of that patient is concentrated around and below 10%, which means, this
patient has a low CAD risk, bordering on intermediate risk.
5.2.5 Assigning a risk category
In order to determine if the patient has a low, medium, or high risk of CAD, we utilize the
probabilities of the discrete distribution. We calculate the patient’s probability of belonging to
each of these groups through summing the probabilities of the DRV outcomes that lie within the
risk value range of each category using the following equations:
Plow =
X
zi10
P (zi)
Pmid =
X
10<zi20
P (zi)
Phigh =
X
zi>20
P (zi)
(5.5)
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Figure 5.2: An example of risk distribution.
Using the category probabilities, we can call the patient’s risk category through a variety of meth-
ods. In this chapter we implement a thresholding method in which we assign the category with the
maximum probability as long as its value is greater than a confidence threshold. If the confidence
threshold was set equal to or greater than 0.5, it ensures that at most one category is called. Increas-
ing the confidence threshold beyond 0.5 controls the level of specificity of the model. Ultimately,
using the confidence threshold provides a versatile framework in which the user can establish a
desired balance between specificity and broadness.
5.2.6 Estimating the distribution parameters
As described earlier, we assume that the values of some of the missing risk factors follow a
normal distribution. For a given risk factor, our strategy uses existing records to calculate an initial
value for the mean and standard deviation. Our method leverages previous diagnosis information
as well as demographic information to fit a mixed linear model. This model optimizes the disease
risk estimates to best fit each demographic group. Therefore, when estimating the CAD risk of
a patient, we chose the coefficient values that have been optimized for the patient’s demographic
group to improve our prediction. As new data is added to the EHR, we fine-tune our estimates by
using the mixed-effects linear model as an informative prior and then applying bayesian updates
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to produce a posterior probability distribution.
To estimate the probability distribution of a risk factor, we start by extracting all the EHR
records that do not have a missing value for that risk factor. We call this data value-only records.
A simple approach would be to directly estimate the distribution parameters using the retrieved
value-only records. However, since the EHR presents a rich resource for information about each
patient, we can incorporate further diagnosis and demographic data into our model to produce bet-
ter estimates. To that end, we extract the diagnosis codes, as well as age and gender information
associated with the value-only records. We call these records enriched-records. The next step is
to choose the diagnosis codes that will be used in improving our model. For each diagnosis code,
we perform a student’s t-test to calculate the association between the diagnosis code presence and
the risk-factor’s value. To avoid group-size imbalance, we only include diagnosis codes whose
frequency ranges between 15% and 85% of the total number of records. After calculating the as-
sociations, we filter out the diagnosis codes whose p-value is larger than the significance threshold
(0.001). We use the significant diagnosis codes as fixed-effects covariates in our model. Further-
more, we divide the patients into 5-year age groups, similar to those used in the FRS. We use the
age and gender groups as random-effect terms in order to account for the variation within these
groups. This is formulated in Eq. 5.6.
riskfactor = X + Zu+  (5.6)
where X represents the matrix of fixed-effects covariates and  represents their correspond-
ing coefficients. Each column in X represents a diagnosis code, whereas each row represents a
patient. Z represents the random effects where each row represents a patient and each column rep-
resents an age-gender group (e.g Male AND 40-45 years old). u is a column vector represented as
u  N(0; G). G is the variance-covariance matrix of the random effects given in Eq. 5.7. After
fitting the above model, each group will have optimized coefficient values. Consequently, each
group will have a group-specific mean value which could be used in the risk estimation process
described above. The standard deviation can be directly estimated from the residuals of the model.
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G =
264 2intercept 2intercept;slope
2intercept;slope 
2
slope
375 (5.7)
Due to the dynamic nature of the EHR, new records are constantly being added. This presents
an opportunity to improve the initial mixed-effects model as new data becomes available. This is
done using bayesian updating which is based on the Bayes rule shown in Eq. 5.8.
P (XjY ) = P (Y jX) P (X)
P (Y )
(5.8)
Where X represents the coefficient distributions, Y represents the data, P (Y jX) is the like-
lihood function, P (X) is the prior distribution, and P (Y ) are the observed probabilities. In our
approach, we utilize a bayesian update method based on Gibbs sampling. The sampler aims to
update the coefficients matrices X as well as as the intercepts of each group. It assumes each
coefficient and intercept follows a normal distribution centered at the initial value determined by
the mixed-effects model. The initial standard deviation of the coefficient distribution is arbitrarily
set to one. The Gibbs sampler then proceeds in an iterative process, where it attempts to estimate
the distribution of one coefficient while fixing all other coefficients. This is further illustrated in
Algorithm 1.
Initialize x(0)
for i = 1; 2; ::: do
x
(i)
1  p(X1 = x1jX2 = x2; X3 = x3; :::)
x
(i)
2  p(X2 = x2jX1 = x1; X3 = x3; :::)
x
(i)
3  p(X3 = x3jX1 = x1; X2 = x2; :::)
...
end
Algorithm 1: Bayesian updating using Gibbs sampling.
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5.2.7 Procedure
The proposed CAD risk estimation method can be summarized in a series of steps. Starting
with an EHR record r with a missing value for risk factor x, the following steps should be executed:
1. Extract r’s age, gender, and the diagnosis codes associated with x.
2. Estimate r’s mean and standard deviation using the mixed-effects model in Eq. 5.6.
3. Use Eq. 5.1 to calculate the probabilities of the score outcomes for the risk factor x.
4. Calculate the outcomes of the FRS points total using Eq. 5.4.
5. Find the class probabilities and assign a risk category using Eq. 5.5. If no category exceeds
the confidence threshold, r is labeled as an unclassifiable record.
5.3 Results
In this section, we study the performance of our risk estimation methodology in the presence
of missing data. We study several aspects of our method: We first evaluate the benefit of using a
probabilistic approach in comparison to point-estimate approaches previously utilized in the EHR
risk estimation literature. We then study the impact of using different confidence thresholds on the
error as well as on the number of unclassified samples. After that, we examine the advantages of
incorporating patient information and utilizing a mixed-effects linear model as our initial model.
Finally, we divide the EHR records into batches, which we then use in successive bayesian updates.
The goal of the latter analysis is to study the effect of bayesian updating on the performance of the
model.
In all experiments, we reserve the Complete records dataset, described earlier, for testing our
strategy. We employ a bootstrapping method to better evaluate the performance metrics. In each
experiment, we apply the risk estimation methods to 500 bootstrapped samples extracted from the
Complete records. We then calculate the performance metrics over the bootstrapped samples and
repeat the process for 1000 iterations. We used the BP-Only and CHL-Only datasets in the training
75
Figure 5.3: The error rates and number of unclassified records for different CAD risk estimation
methods.
process. This insures that the tests are performed on an independent dataset where there is no
overlap between the records used in training and testing. For each record, we calculate the true
risk class, whether low, mid, or high, as described in the FRS procedure. We then calculate the
predicted risk class and check if there is a mismatch between the true and predicted classes. In
this setup, we report the error as the average number of mismatches encountered in bootstrapped
samples. We store the average error from each iteration to construct the distribution of error rates.
We also calculate and store the average number of unclassified records for our method. From the
Complete records dataset, we simulate missing data according to three scenarios encountered in
real EHR data: i) missing Bloop Pressure values, ii) missing Cholesterol values, and iii) missing
both Blood Pressure and Cholesterol values.
The first experiment studies the benefit of using the proposed probabilistic approach compared
to other approaches. We utilize the BP-Only and CHL-Only datasets to optimize the parameters of
the mixed-effects linear model. We then use our methods to calculate the predicted risk classes and
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then calculate the error as described earlier. We compare this method to i) the mean imputation
(MI) method, where the mean value is substituted in the entries with missing data. ii) Multiple
imputations by Chained Equations (MICE), and iii) linear point estimation. We provide MICE
and LPE with each patient’s diagnosis and demographic data to obtain the best performance out of
these models and to enable a fair comparison with our method. We chose a value for the confidence
threshold such that the average number of unclassified records remained under 25%. The results
of the comparison are presented in Figure 5.3. As could be seen from the figure, our method
significantly outperforms the other methods and has succeeded in producing a substantially lower
classification error. This was achieved by filtering out the low confidence samples which have a
high probability of being classified erroneously.
To further analyze the relationship between the confidence threshold, error rate, and number of
unclassified samples, we varied confidence threshold between 0.5 and 0.95 and observed the results
for each dataset (See Figure 5.4). The first observation from this data is that the error rate decreases
steadily as the confidence threshold increases, regardless of the type of missing information. We
also notice that the variance of the error rate decreases as well. Higher confidence thresholds filter
out the marginal cases which might add variation to the error rate. As for unclassified records,
their rate increases rapidly as the confidence threshold increases. Therefore, a trade-off should be
reached to determine a tolerated error rate while ensuring that a sufficient number of records are
classified. Our second observation is that the error rates vary significantly between the missing
Blood Pressure scenario and the missing Cholesterol scenario. The error encountered with missing
Cholesterol is significantly higher for two reasons: the weight of Cholesterol information in the
FRS system is larger than that of Blood Pressure. Therefore, a slightly incorrect prediction of the
Blood Pressure interval might not have a significant impact on the total risk score and consequently,
the risk category. However, the same cannot be said about Cholesterol. The second reason for the
high error rate in the Cholesterol scenario is that Cholesterol values have a larger variation than
Blood Pressure. This results in a wider probability distribution and therefore less differentiation
between risk classes.
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The third step of our analysis was to study the advantage of employing a mixed-effects linear
model which incorporates diagnosis information as well as gender and age group information into
the estimation. We compare the mixed-effects model to a basic approach where all samples belong
to one group and the distribution parameters are estimated directly through fitting a normal distri-
bution. In performing this analysis, we utilized the BP-Only and CHL-Only datasets to train our
model and estimate the required parameters. We implemented the bootstrapping method described
above to test the performance of the two approaches across the three missing data scenarios. We
varied the confidence threshold value to study the different effects it has on the error rate and the
number of unclassified samples. The results of this analysis for the basic method are displayed in
Figure 5.5. When we compare Figures 5.4 and 5.5, the major observation that could be made is
that the results of the basic approach appear to follow a step-shaped curve. This is expected: since
all the missing values in the basic approach are estimated from the same distribution, it is expected
that the results would be more uniform. The difference between risk values is driven by the other
FRS risk factors that did not have missing values. Consequently, this results in the step-shape of
Figure 5.5. Our approach, on the other hand, personalizes the fitted distribution according to the
patient’s diagnosis and demographic information. This results in the smoother patterns in Figure
5.4. A major advantage of using our method is that it enables the researcher to control the unclas-
sified samples rate more effectively. For example, in the "No Blood-Pressure Info" scenario, if we
want to limit the unclassified samples rate to 20%, we have to choose the confidence threshold to
be 0.675 for the basic method. Consequently, the mean error rate for this confidence threshold is
11.2%. On the other hand, for our approach, we can choose the confidence threshold to be 0.75
whose mean error rate is 8.9%.
The final part of our analysis investigated the advantage of using bayesian updating to improve
the performance of our model. To implement this analysis, we divided the BP-Only and CHL-
Only datasets into batches of 500 samples. We used a batch of 500 samples to train our prior
model, then used the remaining 500-sample batches to update the parameters the model. Similar
to the previous experiments, we implemented a bootstrapping method using the Complete dataset
80
Fi
gu
re
5.
6:
T
he
er
ro
rr
at
e
an
d
nu
m
be
ro
fu
nc
la
ss
ifi
ed
re
co
rd
s
af
te
rB
ay
es
ia
n
up
da
tin
g.
81
to test the performance of the model. The results of this analysis are presented in Figure 5.6 which
shows the performance metrics of the model at different update stages for a range of confidence
thresholds. Unfortunately, neither the error rate nor the number of unclassified samples improved
as new data was incorporated into the model. Bayesian updating was unable to improve upon the
prior model. This could mean that the prior model is capable of explaining the variation in the
dataset.
Instead of bayesian updating, one way to improve the results of our model is to repeat the co-
variate identification process as new data is made available. Having more samples provides more
power to find additional associations between diagnosis codes and EHR numerical fields. There-
fore, more fixed-effects covariates could be added to the model which most likely would result in
a performance improvement. It is worth mentioning that the covariates did not change when we
applied the prior construction process using 500 samples verses when we used 4000 samples. This
increase in sample size did not provide a sufficient increase in the power of association detection.
Since we are limited by the number of samples we have, we were unable to test this hypothesis
using a larger sample size. Therefore, we could not verify that increasing the sample size could
indeed drive the detection of more associations.
5.4 Conclusion
In this chapter, we introduced a probabilistic distribution-based technique for performing CAD
risk assessment from incomplete EHR data. For each patient record, our method leverages existing
patient data to produce a probability distribution for the patient’s CAD risk. The method uses
mixed-effects linear modeling to incorporate the patient’s diagnosis and demographic information
into the risk estimation process. The risk distribution is then updated using a Bayesian framework
which utilizes information from patients that have similar records to the target patient. Our method
produces a risk classification as well as a confidence value, which could be used to filter out error
prone low confidence classifications. We evaluated the performance of our method using various
missing data patterns. We then compared the proposed method to popular imputation techniques
that have been used in the context of EHR risk analysis. The results of this comparison showed
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that our method significantly outperforms traditional imputation strategies. We performed our
experiments on real EHR data. In future work, we plan to extend the proposed imputation strategy
to other CAD risk assessment models. Furthermore, we plan to study the effect of integrating
genetic data with EHR records to produce accurate risk assessment.
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6. CONCLUSION
Genomics and Electronic Health Records hold great potential for improving the quality of
healthcare delivery. The adoption of these technologies has been hindered by numerous complex
factors. In this dissertation, we identified the major technical challenges facing the integration of
genomics and EHRs into clinical settings. We presented methods to overcome some of the main
challenges of this integration. This final chapter recaps the topics discussed in each chapter of the
dissertation and summarizes the results of this work.
Chapter 2 began by identifying the different aspects of genomic NGCDS integration. For each
aspect, the chapter described the technologies and algorithms that it encompasses. The chapter
then discussed the genomic challenges of NGCDS and presented possible resolution directions.
Chapter 3 proposed an accelerated method for processing raw genomic data. This is accom-
plished through a combination of distributed, multicore, and GPU computing techniques. The
proposed design exploits the GPU’s massive parallelism to hide memory access latency by align-
ing hundreds of reads concurrently. Concurrent with GPU alignment, the algorithm uses the CPU’s
multiprocessing capability to load, process, and write batches of reads concurrently. We compared
our tool with the BWA mem alignment tool and achieved speedups reaching up to 28.12x. We
demonstrated the algorithm’s ability to handle gapped and un-gapped alignment efficiently for a
varying number of mismatches. Finally, we demonstrated the algorithm’s ability to scale as the
number of reads increases. We believe that this type of parallelism is essential for large-scale
implementations of genomic applications in the NGCDS workflow.
Chapter 4 proposed a data representation and compression method to store the genetic variant
information a database schema. This schema allows for health information and genomic data to be
stored within the same relational database. Adopting a database representation is important for de-
veloping genomic web applications and service-oriented architecture (SOA) genomics frameworks
[7] [8]. In this chapter we introduced a genotype encoding technique based on 2D sparse bitmaps.
The encoding was designed to achieve high compressibility while minimizing access time. Using
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this approach, we were able to reduce the SNP storage space to 10.5% of its original size while
achieving a 100 fold speedup. Furthermore, we compared our approach to the genotype encoding
of the popular Ensembl Variant Database and achieved database size reductions reaching up to
47.33% without compromising access time.
Finally, Chapter 5 focused on the EHR challenges within NGCDS. EHR applications face a
unique type of challenge that originates from the nature of health data. Since EHR entries mainly
consists of the medical information relevant to the patient’s condition at a particular visit, the re-
sulting entry will have a sparse nature and will include many missing values. This significantly
reduces the ability for conducting patient-level health analysis using EHR data. Chapter 5 pro-
posed a probabilistic model to produce accurate patient-level disease risk estimates. The proposed
method leverages existing patient data to produce a probability distribution for the patient’s CAD
risk. We evaluated the performance of the proposed method using various missing data patterns
and compared it to competing methods. The results of this comparison showed that our method
significantly outperforms traditional EHR-based risk estimation strategies. We believe that this
method could significantly enhance the efficiency of disease prevention and early detection efforts.
We hope that the work presented in this dissertation could help alleviate some of the obstacles
standing in the way of the implementation and adoption of NGCDS. By identifying the major
challenges of NGCDS and then tackling key computational and analytical challenges, we believe
that this work sets the stage for future research on this topic. Finally, we reemphasize our belief
that the adoption of NGCDS holds significant promise for improving the the state of healthcare
and conquering disease.
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